Scorpius (SCPX) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2014	Mar. 27, 2014
Document and Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Entity Registrant Name	'HEAT BIOLOGICS, INC.	'	'
Entity Central Index Key	'0001476963	'	'
Current Fiscal Year End Date	'--12-31	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	6,452,341	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$29,384,995

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$4,566,992	$5,030
Short term investments	17,297,165	'
Related party receivable	24,946	9,571
Prepaid expenses and other current assets	1,066,638	58,436
Total Current Assets	22,955,741	73,037
Property and Equipment, net	53,753	10,782
Other Assets	'	'
Restricted cash	1,252	26,214
Debt issuance costs, net	'	28,229
Deposits	9,320	9,320
Total Other Assets	10,572	63,763
Total Assets	23,020,066	147,582
Current Liabilities	'	'
Accounts payable	651,917	505,471
Accrued expenses and other payables	503,050	129,208
Accrued interest	25,364	13,763
Notes payable - current portion	'	66,806
Total Current Liabilities	1,180,331	715,248
Long Term Liabilities	'	'
Notes payable - less current portion	'	658,194
Convertible notes payable	'	197,099
Stock warrants liability	122,590	92,150
Total Liabilities	1,302,921	1,662,691
Stockholders' Equity (Deficit)	'	'
Common stock, $.0002 par value; 50,000,000 shares authorized, 6,375,426 and 2,144,542 shares issued and 6,375,426 and 1,858,971 shares outstanding at December 31, 2013 and 2012, respectively	961	405
Additional paid in capital	34,337,591	4,495,832
Deficit accumulated during the development stage	-12,346,630	-5,935,282
Total Stockholders' Equity (Deficit)	21,991,922	-1,438,848
Non-Controlling Interest	-274,777	-76,261
Total Stockholders' Equity (Deficit) - Heat Biologics, Inc.	21,717,145	-1,515,109
Total Liabilities and Stockholders' Equity (Deficit)	23,020,066	147,582
Series 1 Preferred Stock [Member]	'	'
Stockholders' Equity (Deficit)	'	'
Series preferred stock	'	11
Series A Preferred Stock [Member]	'	'
Stockholders' Equity (Deficit)	'	'
Series preferred stock	'	$186

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	6,375,426	2,144,542
Common stock, shares outstanding	6,375,426	1,858,971
Series 1 Preferred Stock [Member]	'	'
Preferred Stock, par value per share	$0.00	$0.00
Preferred stock, shares authorized	112,500	112,500
Preferred stock, shares issued	0	112,500
Preferred stock, shares outstanding	0	112,500
Series A Preferred Stock [Member]	'	'
Preferred Stock, par value per share	$0.00	$0.00
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	1,863,128
Preferred stock, shares outstanding	0	1,863,128

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		67 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Consolidated Statements of Operations [Abstract]	'	'	'
Grant awards	'	$3,110	$585,589
Operating expenses:	'	'	'
Research and development	2,737,688	902,938	6,095,170
Clinical and regulatory	1,397,157	253,189	1,825,000
General and administrative	2,429,796	1,189,660	4,725,322
Total operating expenses	6,564,641	2,345,787	12,645,492
Loss from operations	-6,564,641	-2,342,677	-12,059,903
Interest income	10,068	2	10,755
Other income (expense)	23,828	-7,257	15,045
Interest expense	-79,119	-101,086	-298,580
Total non-operating expenses	-45,223	-108,341	-272,780
Loss from continuing operations	-6,609,864	-2,451,018	-12,332,683
Loss from discontinued operations	'	-20,129	-288,724
Net Loss	-6,609,864	-2,471,147	-12,621,407
Net loss - non-controlling interest	-198,516	-50,947	-274,777
Beneficial conversion charge	-2,300,000	'	-2,300,000
Preferred stock dividend	-361,668	'	-361,668
Net loss attributable to common stockholders	($9,073,016)	($2,420,200)	($15,008,298)
Net loss per share attributable to common stockholders-basic and diluted	($2.42)	($1.32)	'
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted	3,747,357	1,831,769	'

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders Equity (Deficit) (USD $)	Total	Series 1 Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	APIC [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]
Balance at Jun. 09, 2008	'	'	'	'	'	'	'	'
Balance, Shares at Jun. 09, 2008	'	'	'	'	'	'	'	'
Common Stock Issued transaction one	321	'	'	'	321	'	'	'
Common Stock Issued transaction two	60	'	'	'	60	'	'	'
Common Stock Issued transaction three	42	'	'	'	42	'	'	'
Common Stock Issued non-cash consideration for rent	4,104	'	'	'	'	4,104	'	'
Net Loss	-281,971	'	'	'	'	'	-281,971	'
Balance at Dec. 31, 2008	-277,444	'	'	'	423	4,104	-281,971	'
Common Stock Issued transaction one	14	'	'	'	14	'	'	'
Common Stock Issued transaction two	5	'	'	'	5	'	'	'
Common Stock Issued transaction three	23	'	'	'	23	'	'	'
Common Stock Issued non-cash consideration for rent	5,760	'	'	'	'	5,760	'	'
Common Stock Cancelled	'	'	'	'	-65	65	'	'
Preferred Stock Issued transaction one	250,000	'	11	'	'	249,989	'	'
Stock based compensation	13,364	'	'	'	'	13,364	'	'
Net Loss	-423,439	'	'	'	'	'	-416,789	-6,650
Balance at Dec. 31, 2009	-431,717	'	11	'	400	273,282	-698,760	-6,650
Common Stock Issued non-cash consideration for rent	5,760	'	'	'	'	5,760	'	'
Stock based compensation	30,791	'	'	'	'	30,791	'	'
Stock issuance costs	-7,584	'	'	'	'	-7,584	'	'
Net Loss	'	'	'	'	'	'	-711,438	-10,406
Balance at Dec. 31, 2010	-1,124,594	'	11	'	400	302,249	-1,410,198	-17,056
Preferred Stock Issued transaction one	154,255	'	7	'	'	154,248	'	'
Stock based compensation	91,984	'	'	'	'	91,984	'	'
Preferred Stock Issued Preferred Series A Converted to Preferred Series 1	'	11	-11	'	'	'	'	'
Stock issuance costs	-17,581	'	-17,581	'	'	'	'	'
Notes Payable Converted to Preferred Stock	2,674,980	'	127	'	'	2,674,853	'	'
Net Loss	-2,113,142	'	'	'	'	'	-2,104,884	-8,258
Balance at Dec. 31, 2011	-334,098	11	134	'	400	3,205,753	-3,515,082	-25,314
Common Stock Issued transaction one	825	'	'	'	'	825	'	'
Common Stock Issued transaction two	10,500	'	'	'	'	10,495	'	'
Preferred Stock Issued transaction one	100,000	'	5	'	'	99,995	'	'
Preferred Stock Issued transaction two	83,334	'	4	'	'	83,330	'	'
Preferred Stock Issued transaction three	900,000	'	43	'	'	889,957	'	'
Stock based compensation	217,896	'	'	'	'	217,896	'	'
Stock issuance costs	-22,419	'	'	'	'	-22,419	'	'
Common Stock Issued: Vesting of restricted stock	'	'	'	'	'	'	'	'
Net Loss	-2,471,147	'	'	'	'	'	-2,420,200	-50,947
Balance at Dec. 31, 2012	-1,515,109	11	186	'	405	4,495,832	-5,935,282	-76,261
Common Stock Issued transaction one	25,110,540	'	'	'	540	25,110,000	'	'
Preferred Stock Issued transaction one	5,050,090	'	'	189	'	5,049,901	'	'
Stock based compensation	571,924	'	'	'	'	571,924	'	'
Common Stock Issued: Preferred Series 1 Converted to Common Stock	'	-11	'	'	'	11	'	'
Common Stock Issued: Preferred Series A Converted to Common Stock	'	'	-186	'	'	186	'	'
Common Stock Issued: Preferred Series B Converted to Common Stock	'	'	'	-189	'	189	'	'
Stock issuance costs	-944,478	'	'	'	'	-944,478	'	'
Exercise of stock options	54,042	'	'	'	16	54,026	'	'
Common Stock Issued: Vesting of restricted stock	'	'	'	'	'	'	'	'
Common Stock Issued: Preferred Stock Dividend	'	'	'	'	'	'	'	'
Net Loss	-6,609,864	'	'	'	'	'	-6,411,348	-198,516
Balance at Dec. 31, 2013	$21,717,145	'	'	'	$961	$34,337,591	($12,346,630)	($274,777)

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders Equity (Deficit) (Parenthetical) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

Dec. 31, 2012

Jun. 30, 2009

Apr. 30, 2009

Jan. 31, 2009

Jul. 31, 2008

Jun. 30, 2008

Dec. 31, 2013

Jul. 31, 2013

Dec. 31, 2011

Dec. 16, 2011

Apr. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Nov. 30, 2009

Apr. 27, 2012

Apr. 03, 2012

Mar. 07, 2012

Dec. 20, 2011

Nov. 03, 2009

Mar. 31, 2013

Mar. 25, 2013

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Equity Issuance [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.10

$2.10

$2.10

$2.10

$2.22

'

$2.67

Common Stock Issued transaction one, shares

1,087

'

'

60,871

'

1,359,559

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued transaction two, shares

21,740

'

21,835

'

260,870

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued transaction three, shares

'

'

98,626

'

184,048

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Cancelled, shares

'

-282,672

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Issued transaction one, shares

'

'

'

'

'

'

'

'

'

'

'

47,619

73,455

'

112,500

'

'

'

'

'

1,891,419

'

Preferred Stock Issued transaction two, shares

'

'

'

'

'

'

'

'

'

'

39,683

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Issued transaction three, shares

'

'

'

'

'

'

'

'

'

'

428,571

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Issued Preferred Series A Converted to Preferred Series 1, shares

'

'

'

'

'

'

'

'

112,500

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued: Preferred Series 1 Converted to Common Stock, shares

'

'

'

'

'

'

'

49,960

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued: Preferred Series A Converted to Common Stock, shares

'

'

'

'

'

'

'

810,057

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued: Preferred Series B Converted to Common Stock, shares

'

'

'

'

'

'

'

836,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable Converted to Preferred Stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

1,273,800

'

'

'

'

'

'

'

'

Conversion price per share

'

'

'

'

'

'

'

'

'

$2.22

'

'

'

$2.10

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

'

'

'

'

80,706

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued: Vesting of restricted stock, shares

97,007

'

'

'

'

'

2,899

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued: Preferred Stock Dividend, shares

'

'

'

'

'

'

'

36,167

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		67 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash Flows from Operating Activities	'	'	'
Net Loss	($6,609,864)	($2,471,147)	($12,621,407)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	6,348	2,587	9,559
Amortization of debt issuance costs	28,229	58,458	126,742
Amortization of bond premium	50,781	'	50,781
Re-measurement of fair value of stock warrants liability	30,440	3,540	35,020
Non-cash consideration for rent	'	'	15,624
Stock based compensation	571,924	217,896	925,959
Increase (decrease) in cash arising from changes in assets and liabilities:	'	'	'
Related party receivable	-15,375	-9,571	-24,946
Prepaid expenses and other current assets	-1,008,202	-52,843	-1,066,638
Restricted cash	24,962	-24,502	-1,252
Deposits	'	200	-9,320
Accounts payable	146,446	85,323	651,917
Accrued expenses and other payables	373,842	103,307	503,050
Accrued interest	11,601	13,077	76,635
Net Cash Used in Operating Activities	-6,388,868	-2,073,675	-11,328,276
Cash Flows from Investing Activities	'	'	'
Purchases of short term investments	-17,347,946	'	-17,347,946
Purchase of property and equipment	-49,319	-1,780	-63,312
Net Cash Used in Investing Activities	-17,397,265	-1,780	-17,411,258
Cash Flows from Financing Activities	'	'	'
Proceeds from initial public offering, net of underwriting discounts	25,110,000	'	25,110,000
Related party payable	'	-12,500	'
Borrowings on notes payable	200,000	950,000	1,150,000
Borrowings on line of credit	'	'	273,427
Payments on notes payable	-925,000	-225,000	-1,150,000
Payments on line of credit	'	'	-273,427
Issuance of convertible notes payable, net of issuance costs	'	197,099	2,781,636
Payments on convertible notes payable	-197,099	'	-197,099
Issuance of common stock	540	11,325	12,330
Exercise of stock options	54,042	'	54,042
Stock issuance costs	-944,478	-22,419	-992,062
Net Cash Provided By Financing Activities	28,348,095	1,981,839	33,306,526
Net Increase in Cash and Cash Equivalents	4,561,962	-93,616	4,566,992
Cash and Cash Equivalents - Beginning of Period	5,030	98,646	'
Cash and Cash Equivalents - End of Period	4,566,992	5,030	4,566,992
Supplemental Disclosure for Cash Flow Information	'	'	'
Interest paid	60,922	29,049	135,606
Supplemental Schedule of Noncash Investing and Financing Activities	'	'	'
Beneficial conversion charge	2,300,000	'	2,300,000
Issuance of preferred stock warrants and debt issuance costs	'	31,680	87,570
Cancellation of common stock	'	'	65
Non-cash consideration for rent	'	'	15,624
Non-cash conversion of preferred stock into common stock	386	'	386
Preferred stock dividend	361,668	'	361,668
Series A Preferred Stock [Member]	'	'	'
Cash Flows from Financing Activities	'	'	'
Issuance of preferred stock	'	1,083,334	1,487,589
Series B-1 Preferred Stock [Member]	'	'	'
Cash Flows from Financing Activities	'	'	'
Issuance of preferred stock	$5,050,090	'	$5,050,090

Organization

Organization	12 Months Ended
	Dec. 31, 2013
Organization [Abstract]	'
Organization	'
	1
	Organization
	Heat Biologics, Inc. ("Heat" or "the Company"), was incorporated in 2008 pursuant to the laws of the state of Delaware. Heat Biologics, Inc. is a development stage company focused on the development and commercialization of ImPact Therapy, a platform technology that offers a novel approach to treating cancer and other diseases by using live, modified cell lines to activate the immune system against specific defined targets. Heat is currently in Phase II clinical trials with its first drug for patients with advanced non-small cell lung cancer.  During 2010 and part of 2011, Heat was headquartered in Miami Beach, Florida. In July 2011, Heat moved its headquarters to Chapel Hill, North Carolina.
	Heat has owned 92.5% interests in two subsidiaries, Heat Biologics I, Inc. and Heat Biologics II, Inc. since their incorporation in the state of Delaware and commencement of operations on April 28, 2009. In April of 2012, the Board of Directors approved the sale of Heat's entire 92.5% interest in Heat II. An independent appraisal report, issued on April 18, 2012, was concurrently approved by the Board as an accurate assessment of Heat II's fair value of $0.0025 per share. On June 25, 2012 a stock purchase agreement was executed for the purchase of 3,700,000 shares of Heat II common stock by a related party. The operations of Heat II during fiscal year 2012 through June 25, 2012, and inception to date, are presented in the accompanying consolidated statements of operations as a loss from discontinued operations. At December 31, 2013 and 2012, there were no assets or liabilities on the consolidated balance sheets related to the discontinued operations of Heat II.
	On May 30, 2012, Heat formed two-wholly owned subsidiaries, Heat Biologics III, Inc. ("Heat III") and Heat Biologics, IV, Inc. ("Heat IV"). Heat also formed Heat Biologics GmbH (Heat GmbH), a wholly-owned limited liability company, organized in Germany on September 11, 2012.
	Heat's product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of Heat's strategy is to develop and commercialize some of its product candidates by continuing existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2
	Summary of Significant Accounting Policies
	Basis of Accounting
	The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Activities during the development stage include developing the business plan, raising capital, and developing the Company's platform technology.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. ("Heat I") and Heat Biologics II, Inc. ("Heat II"), Heat Biologics III, Inc. ("Heat III"), Heat Biologics IV, Inc. ("Heat IV") and Heat Biologics GmbH. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2013 and 2012, Heat held a 92.5% controlling interest in Heat I and accounts for its less than 100% interest in the consolidated financial statements in accordance with U.S. GAAP. Accordingly, the Company presents non-controlling interests as a component of stockholders' equity (deficit) on its consolidated balance sheets and reports non-controlling interest net loss under the heading "net loss - non-controlling interest" in the consolidated statements of operations. In June 2012, the Company sold its entire 92.5% interest in Heat II. The operations of Heat II through June 25, 2012, and inception to date, are presented in the accompanying consolidated statements of operations as a loss from discontinued operations.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, income taxes and stock-based compensation. Actual results may differ from those estimates.
	Cash and Cash Equivalents and Restricted Cash
	The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $1,252 and $26,214 at December 31, 2013 and 2012, respectively. The United States Patent and Trade Office ("USPTO") requires the Company to maintain an account with a minimum of $1,000 to be used to pay fees associated with new trademarks of the Company and one of the Company's lenders required a minimum $25,000 cash balance to be maintained with the lending bank during 2012.
	Concentration of Credit Risk
	At times, cash balances may exceed the Federal Deposit Insurance Corporation ("FDIC") insurable limits. The Company has never experienced any losses related to these balances. All of the Company's cash balances were fully insured at December 31, 2012. As of December 31, 2013, cash amounts in excess of $250,000 were not fully insured. The uninsured cash balance as of December 31, 2013 was $4,046,451. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.
	Debt Issuance Costs, net
	Debt issuance costs include the costs incurred to obtain financing, including the fair value of preferred stock warrants at the date of their issuance, and are amortized using the straight-line method, which approximates the effective interest method, over the life of the related debt. Debt issuance costs are included in the accompanying consolidated balance sheets net of amortization.
	Property and Equipment
	Property and equipment are stated at cost and are capitalized if the cost exceeds $500. Depreciation is calculated using the straight-line method and is based on estimated useful lives of 3 years for computer equipment and seven years for furniture and fixtures.
	Stock Warrants Liability
	In December 2011 and August 2012, the Company entered into a promissory note with each of two lenders and issued preferred stock warrants to each lender as consideration. The Company has accounted for these freestanding warrants as liabilities at their fair value on the accompanying consolidated balance sheets. The warrants are subject to re-measurement at each balance sheet date, and the change in fair value, if any, is recognized as other income (expense). The warrants converted from preferred stock warrants into warrants to purchase common stock upon the completion of the initial public offering in July 2013 and the number of shares were adjusted for the 1-for-2.3 reverse stock split. However, since the warrants still have an anti-dilution provision, they remain liabilities and are subject to re-measurement at each balance sheet date. The warrants are valued using a Monte Carlo simulation which is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company's future expected stock prices and minimizes standard error.
	Significant assumptions used in the valuation of the stock warrants liability were as follows:
		December 31,
		2013				2012
	Exercise price	$	4.83			$	4.83
	Risk-free interest rate		2.75	%			1.78	%
	Expected volatility		71.6-71.9	%			75.6-76.3	%
	Expected life (years)		7.96-8.6				10
	Expected dividend yield		0	%			0	%
	Beneficial Conversion Feature
	When the Company issues an equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Company's common stock and the effective conversion price of the equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the equity.
	The amount allocated to the beneficial conversion feature is presented as an immediate charge to earnings available to common shareholders for convertible preferred stock instruments that are convertible by the shareholders at any time. In connection with the Company's issuance of Series B-1 Preferred Stock during fiscal year 2013, the Company recorded a beneficial conversion charge of $2.3 million representing the difference between the effective conversion price of $6.14 and the fair value of the Company's common stock as of the Commitment Date of $8.81.
	Net Loss per Share
	Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation.
	Fair Value of Financial Instruments
	The carrying amount of certain of the Company's financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, deposits, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. The carrying value of the Company's notes payable and convertible notes payable at December 31, 2012 approximated fair value because the interest rates under those obligations approximated market rates of interest available to the Company for similar instruments.
	As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level I - Observable inputs such as quoted prices in active markets for identical assets or liabilities.
	Level II - Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level III - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's financial instruments that are measured at fair value on a recurring basis consist only of the stock warrants liability. The Company's stock warrants liability was classified within Level III of the fair value hierarchy and as of December 31, 2013 and 2012.
	The change in the fair value of the Level III warrants liability is summarized below:
	Fair value at December 31, 2012	$	92,150
	Issuances		-
	Change in fair value during the period		30,440
	Fair value at December 31, 2013	$	122,590
	The change in the fair value of the Level III stock warrants liability is summarized below:
		31-Dec-13
		Identical			Observable			Unobservable			Total
		Assets			Inputs			Inputs			December 31,
	Description	(Level 1)			(Level 2)			(Level 3)			2013
	Liabilities measured at fair value
	Stock Warrant Liability	$	-		$	-		$	(122,590	)	$	(122,590	)
	Total Liabilities measured at fair value	$	-		$	-		$	(122,590	)	$	(122,590	)
		31-Dec-12
		Identical			Observable			Unobservable			Total
		Assets			Inputs			Inputs			December 31,
	Description	(Level 1)			(Level 2)			(Level 3)			2012
	Liabilities measured at fair value
	Stock Warrant Liability	$	-		$	-		$	(92,150	)	$	(92,150	)
	Total Liabilities measured at fair value	$	-		$	-		$	(92,150	)	$	(92,150	)
	Marketing
	Marketing costs are expensed as incurred. Marketing expense totaled $135,366 and $5,921 for the years ended December 31, 2013 and 2012, respectively. Marketing expenses from inception through December 31, 2013 totaled $183,274.
	Income Tax
	Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	In accordance with FASB ASC 740, Accounting for Income Taxes, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2013 and 2012, the Company had no unrecognized income tax benefits and correspondingly there is no impact on the Company's effective income tax rate associated with these items. The Company's policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations, As of December 31, 2013 and 2012, the Company had no such accruals.
Stock-Based Compensation
The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model.
Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2013 and 2012 represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received.
Net loss attributable to non-controlling interests
Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. The Company's net loss attributable to non-controlling interests relates to the University's ownership in Heat I, and its ownership interest in Heat II before the divestiture of Heat II on June 25, 2012.
Revenue Recognition
The Company recognizes government grants when there is reasonable assurance that they will comply with the conditions attached to the grants and the grants will be received. The grants are recognized using an income approach and grant revenue is recognized as the related expenses are incurred.
Research and Development
Research and development costs are expensed as incurred. The Company has acquired exclusive licensing rights to intellectual property to further its research and development. These costs are expensed as incurred. The Company also incurs legal costs relating to the filing and application fees for patents which are owned by the universities with which the Company has license agreements. These costs are also expensed as research and development expense as incurred.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2013
Discontinued Operations [Abstract]	'
Discontinued Operations	'
	3
	Discontinued Operations
	In April of 2012, the Company's board approved a plan to sell its 92.5% interest in Heat II to a related party entity. On June 25, 2012, the Company sold all of its interest in Heat II to the related party in exchange for $9,250 in cash and a receivable from the related party of $296,244. The receivable is due in full approximately seven years from the date of the transaction with interest accruing at a rate of 6% per annum. The Company performed a fair value analysis of the receivable from the related party and determined that due to the uncertainty surrounding the collectibility of the receivable, the fair value was $0. The Company's estimate of the fair value of the receivable is based upon several factors including the long-term maturity of the receivable, an analysis of the related party's ability and willingness to pay the receivable given the current financial position, and that fact that Heat II is likely years away from generating product revenues.
	The $9,250 in cash was recorded as a reduction to the loss from discontinued operations in the consolidated statement of operations for the year ended December 31, 2012. The operations of Heat II through June 25, 2012, and inception to date, are presented in the accompanying consolidated statements of operations as a loss from discontinued operations.

Investments

Investments	12 Months Ended
	Dec. 31, 2013
Investments [Abstract]	'
Investments	'
	4.
	Investments
	Investments - Investments in certain securities may be classified into three categories:
	·
	Held-to-maturity -  Debt securities that the Company has the positive intent and ability to hold to maturity are reported at amortized cost.
	·
	Trading securities -  Debt and equity securities that are bought and held principally for the purpose of selling in the near term are reported at fair value with unrealized gains and losses included in earnings.
	·
	Available-for-sale -  Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders' equity.
	The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period. The Company has determined that its debt securities should be classified as held-to-maturity as of December 31, 2013. The Company held no investments at December 31, 2012. This classification was based upon management's determination that it has the positive intent and ability to hold the securities until their maturity dates, as the underlying cash invested in these securities is not required for current operations. Investments consist of short-term FDIC insured certificates of deposit, commercial paper rated A1/P1 or above and corporate notes and bonds rated A and above carried at amortized cost using the effective interest method.
	The following table summarizes information about short term investments at December 31, 2013:
		Amortized		Gross		Estimated
		Cost		Unrealized		Fair Value
				Losses
	Certificates of deposit, commercial paper	$	17,297,165	$	16,493	$	17,280,672
	As of December 31, 2013, the estimated fair value of the investments was less than the amortized cost. Because management intends to hold the investments until their maturity dates, these unrealized losses were not recorded in the consolidated financial statements.
	The maturities of held-to-maturity investments at December 31, 2013 were as follows:
		Less than		Total
		1 Year
	Certificates of deposit, commercial paper	$	17,297,165	$	17,297,165

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
Property and Equipment	'
	5
	Property and Equipment
	Property and equipment are recorded at cost and depreciated using the straight-line method, over estimated useful lives, ranging generally from five to seven years. Expenditures for maintenance and repairs are charged to expense as incurred.
	Property and equipment consisted of the following:
		December 31,
		2013			2012
	Furniture and fixtures	$	10,780		$	10,780
	Computers		13,175			3,213
	Lab equipment		39,357			-
	Total		63,312			13,993
	Accumulated depreciation		(9,559	)		(3,211	)
	Property and equipment, net	$	53,753		$	10,782
	Depreciation expense totaled $6,348 and $2,587 for the years ended December 31, 2013 and 2012, respectively.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	6
	Accrued Expenses
	Accrued expenses consist of the following:
		December 31,
		2013		2012
	Compensation and related benefits	$	356,588	$	105,927
	Accrued patent fees		40,000		20,000
	Miscellaneous expenses		106,462		3,281
		$	503,050	$	129,208

Debt_Issuance_Costs

Debt Issuance Costs	12 Months Ended
	Dec. 31, 2013
Debt Issuance Costs [Abstract]	'
Debt Issuance Costs	'
	7
	Debt Issuance Costs
	In December 2011, the Company recorded $55,890 of debt issuance costs related to the issuance of warrants to purchase Series A Preferred Stock to a lender. The warrants were issued in conjunction with a promissory note issued to the lender. In December 2011, the Company began amortizing the debt issuance costs over the three year term of the promissory note resulting in $883 of interest expense for the year ended December 31, 2011. The note payable associated with the preferred stock warrants was paid in full and terminated during 2012.  The remaining balance of $55,007 was amortized and written off during 2012.
	In August 2012, the Company recorded $31,680 of debt issuance costs related to the issuance of warrants to purchase Series A Preferred Stock to a lender. The warrants were issued in conjunction with a promissory note issued to the lender. At this time, the Company began amortizing the debt issuance costs over the four year term of the promissory note resulting in $3,451 of interest expense for the year ended December 31, 2012.
	Total amortization expense for the debt issuance costs was $28,229 and $58,548 during fiscal year 2013 and 2012, respectively.

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2013
Convertible Notes Payable [Abstract]	'
Convertible Notes Payable	'
	8
	Convertible Notes Payable
	On October 20, 2011, the Company entered into a convertible note agreement with a vendor for an amount up to $950,000. The note accrues 12% simple interest per annum beginning on the day of the first advance. The note is convertible into common or Series A preferred stock at the latest valuation. The type of security converted will depend on whether common or Series A preferred stock is issued as part of a successful future equity raise of at least $7.5 million at the qualified offering price. Unless earlier converted into equity, the note will be payable upon demand after the eighth anniversary of the execution date of the vendor agreement which occurs in October 2019. The agreement allows the vendor to treat unpaid invoices as advances of principal under the promissory note. As of December 31, 2012, the outstanding balance on the note was $197,099. The note payable was terminated and paid off in July 2013.
	Accrued interest on outstanding debt obligations was $0 and $13,763 at December 31, 2013 and 2012, respectively.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
Notes Payable	'
	9
	Notes Payable
	On December 14, 2011, the Company entered into a loan agreement with the North Carolina Biotechnology Center (the "Center") for an amount up to $250,000 to be used by the Company to develop certain of its proprietary technology and processes as defined by the loan agreement during a one year period ended December 14, 2012. The principal of the loan, plus accrued interest, was due in full on December 14, 2014, with annual installments of 5% of the outstanding balance due on December 14, 2012 and 2013. The loan agreement accrues interest at 4.25% per annum beginning on the day of the first advance. As of December 31, 2011, the outstanding balance was $0 and no draw downs occurred during fiscal year 2011. During the year ended December 31, 2012, the Company drew down $225,000 of the loan and then repaid the principal balance, including accrued interest, in full in August 2012. The loan agreement was canceled upon the repayment.
	In conjunction with this loan agreement, the Company issued warrants to purchase 29,762 shares of Series A Preferred Stock with an exercise price of $4.83 per share and an expiration date of December 13, 2021. Per the terms of the warrant agreement, the exercise price of $4.83 per share is subject to adjustment if at any time subsequent to the date of the warrant agreement, Preferred Series A shares are issued at a price less than $4.83 per share. The warrants converted from preferred stock warrants into warrants to purchase common stock upon the completion of the initial public offering in July 2013 and the number of shares were adjusted for the 1-for-2.3 reverse stock split. However, since the warrants still have an anti-dilution provision, they remain liabilities and are subject to re-measurement at each balance sheet date. The total number of warrants post the 1-for-2.3 reverse stock split is 12,940.
	On August 7, 2012, the Company entered into a loan and security agreement ("the Loan and Security Agreement") with a bank. The terms of the agreement provide for a $1,000,000 term loan ("Tranche A") to be available to the Company as of the date of the Loan and Security Agreement. The Tranche A term loan may be increased to $2,775,000 upon the Company receiving grant funding totaling at least $16,000,000. The Tranche A term loan accrues interest monthly at an interest rate of 3% plus Prime or 6% per annum, whichever is greater. The Tranche A term loan principal balance, along with any accrued interest, is to be paid in thirty-six equal monthly installments beginning September 7, 2013 and ending August 7, 2016. As of December 31, 2012, the Company's outstanding principal balance on the Tranche A term loan was $500,000.
	Additionally, the Loan and Security Agreement provides for a term loan in an aggregate principal amount not to exceed $225,000 ("Term Loan B"). Payments of 5% of the outstanding principal balance, plus accrued interest are each due on August 2013 and 2014, with the remaining principal balance, plus all accrued interest, due December 14, 2014. The term loan accrues interest monthly at 4.25% per annum. Proceeds from the $225,000 Term Loan B were used to pay in full the principal balance of the loan with the Center as noted above. On August 27, 2013, the Company repaid the entire outstanding balance on the Tranche A term loan and the Term Loan B with the bank, in the amount of $725,000 and the loan agreement was terminated.
	On January 10, 2013, the Company signed a Second Amendment to its Loan and Security Agreement which granted an extension of credit in the form of a Non-Formula Revolving Line ("the Non-Formula Line") for an amount up to $200,000. This increase in credit was through a limited guaranty by an investor who secured the additional obligation by maintaining as collateral a money market account of a minimum of $200,000 with the bank. This guarantee was only for the amounts arising from the Line. It was the intention of both the investor and the Company that the Line was to be repaid within a reasonable time period after the successful raise of capital but no later than January 9, 2014, the maturity date of the Line. The payoff of the Line would release the investor of its obligation to the bank. The Company borrowed $200,000 on the Line in January 2013, and the entire balance was paid in April 2013.
	In conjunction with the Loan and Security Agreement, the Company issued warrants to the bank to purchase 17,500 shares of Heat's Series A Preferred Stock. The warrants were issued on August 7, 2012 with an initial exercise price of $4.83 per share and expire on August 7, 2022. The warrants converted from preferred stock warrants into warrants to purchase common stock upon the completion of the initial public offering in July 2013 and the number of shares were adjusted for the 1-for-2.3 reverse stock split. However, since the warrants still have an anti-dilution provision, they remain liabilities and are subject to re-measurement at each balance sheet date. The total number of warrants post the 1-for-2.3 reverse stock split is 7,609.

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2013
License Agreements [Abstract]	'
License Agreements	'
	10
	License Agreements
	On July 11, 2008, Heat entered into two agreements with The University of Miami (the "University") to license, from the University, certain technology and processes in various stages of patent pursuit on an exclusive basis for use in its research and development and commercial activities ("License Agreement 03-31, 05-39" and "License Agreement 97-14", or collectively "License Agreements"). Heat has the right to grant sublicenses under the License Agreements.
	Heat is also responsible for all patent costs, past and future, associated with the preparation, filing, prosecution, issuance, and maintenance of United States patent applications. Heat is also required to make minimum royalty payments to the University under the terms of the License Agreements.
	In connection with the License Agreements, Heat agreed to issue to the University 10% of all issued and outstanding common stock in each class and series on a fully-diluted basis together with rights to participate in future stock offerings.
	In April 2009, Heat and the University agreed to amend the original License Agreements of July 11, 2008 to extend the terms of payments. For the additional consideration of $12,500 and additional stock of 2.5% of fully-dilutable shares issued and outstanding for each License Agreement, a revised extension date of August 11, 2009 was granted for all past due license fees and patent costs. Furthermore, the 10% original stock holdings were given assurance of anti-dilution protection until a "Qualified Investment" pursuant to this agreement. This anti-dilution protection has been distinguished with the subsequent agreement described below.
	On June 26, 2009, Heat assigned all rights and obligations of License Agreement 03-31, 05-39 and License Agreement 97-14 to its subsidiaries, Heat II and Heat I, respectively. All previous stock ownership and rights of the University to participate in future stock offerings by Heat were mutually terminated. Heat I and Heat II agreed to issue the University 5% of each subsidiary's issued and outstanding common stock in each class and series on a fully-diluted basis, together with fully-dilutable common shares equal to 2.5% of the total number of shares in each class and series issued outstanding. As a result, the University owns 7.5% of Heat I and Heat II's issued and outstanding common stock. For each agreement, the Company agreed to make minimum royalty payments of $10,000 for three years beginning 2010 due on the anniversary date of the agreements. Beginning in 2013, and thereafter for the life of the agreements, the minimum royalty payments shall be $20,000 due on the same date. A milestone payment is due to the University from the Company no later than March 2022 of $400,000 for License Agreement 03-31, 05-39. Another milestone payment is due no later than May 2017 of $250,000 for License Agreement 97-14.
	In August 2009, Heat II and the University entered into a second amendment ("Amendment 2") to License Agreement 03-31, 05-39 to extend the foregoing payment due dates for all past due license fees and patent costs.
	In August 2009, Heat I and the University entered into a second amendment ("Amendment 2") to License Agreement 97-14 to extend the foregoing payment due dates for all past due license fees and patent costs.
	In February 2010, Heat II and the University entered into a third amendment ("Amendment 4") to License Agreement 03-31, 05-39 to grant back to the University a certain non-exclusive license. In all other respects, the original agreement remained the same.
	On August 30, 2010, Heat entered into an option agreement with the University of Michigan ("University II") to acquire the right to negotiate an exclusive license for certain materials which includes cancer bladder cells and all unmodified derivatives of these cells. An option fee of $2,000 was paid on September 8, 2010 to grant a period of nine months for this consideration. In July 2011, the Company exercised the option to acquire the license for $10,000.
	In October 2010, Heat II and the University entered into a fourth amendment ("Amendment 5") to License Agreement 03-31, 05-39 to grant to the licensor a non-exclusive license right for certain technology as research reagents and research tools.
	On December 12, 2010, Heat II entered into another license agreement ("I-176") with the University for one component of complimentary technology to the July 11, 2008 agreement. Heat II agreed to pay the University a license fee of $50,000 and a reimbursement of $15,797 for past patent fees. Heat II also agreed to make a minimum royalty payment of $10,000 during 2012.
	On February 18, 2011, Heat I entered into a license agreement ("SS114A") with the University to obtain additional technology related to License Agreement 97-14. Heat I agreed to reimburse the University for all past patent costs of $37,381. As partial consideration for the license, Heat II agreed to grant back certain exclusive rights to the University.
	On February 18, 2011, Heat I entered into a license agreement ("143") with the University to obtain additional technology related to License Agreement 97-14. In consideration for the license, Heat I agreed to pay the University a fee of $50,000 and reimburse them for past patent costs of $14,158.
	On February 18, 2011, Heat I entered into a license agreement ("J110") with the University to obtain additional technology related to License Agreement 97-14. In consideration for the license, Heat I agreed to pay the University a fee of $10,000 and reimburse them for past patent costs of $1,055.
	On February 18, 2011, Heat I entered into a license agreement ("D-107") with the University to obtain additional technology related to License Agreement 97-14.
	On April 12, 2011, Heat entered into a non-exclusive evaluation and biological material license agreement with a not-for-profit corporation for evaluation and production of vaccines. In consideration for the evaluation and commercial use license, Heat agreed to pay the not-for-profit corporation a fee of $5,000 and $50,000, respectively. Heat has the option to renew the license once the original term has expired.  Milestone payments are due upon certain events agreed upon by Heat and the not-for-profit corporation.
	At December 31, 2011, Heat owed the University $160,000 in unpaid license fees. At December 19, 2012, Heat I owed the University $102,784 in unpaid license fees. Heat entered into a payment agreement on December 19, 2012 to extend the payment due of Heat I obligations until the earlier of the closing of a Series B financing round or June 1, 2013.  As consideration for the extension of payment Heat I made an additional payment to the University equal to 18% annual interest of the outstanding balance on or before the due date or at the University's option convert into shares of preferred stock according to the terms stipulated in the agreement.
	Future minimum royalty payments as of December 31, 2013 are as follows:
	Year ended December 31,
	2014	$	30,000
	2015		30,000
	2016		30,000
	2017		280,000
	2018		30,000
	Thereafter		120,000
	Total	$	520,000

Stock_Warrants_Liability

Stock Warrants Liability	12 Months Ended
	Dec. 31, 2013
Stock Warrants Liability [Abstract]	'
Stock Warrants Liability	'
	11
	Stock Warrants Liability
	The summary of stock warrants liability activity for the years ended December 31, 2013 and 2012 is as follows:
		Number of		Weighted		Weighted		Weighted
		Warrants		Average		Average		Average
				Exercise		Remaining		Grant
				Price		Contractual		Date
						Life (in years)		Fair Value
	Outstanding at December 31, 2011		12,940	$	4.83		9.9	$	1.91
	Granted		7,609	$	4.83		9.9	$	1.81
	Exercised		-		-		-		-
	Expired/cancelled		-		-		-		-
	Outstanding at December 31, 2012		20,549	$	4.83		8.9	$	1.64
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired/cancelled		-		-		-		-
	Outstanding at December 31, 2013		20,549	$	4.83		8.2	$	5.95
	The aggregate intrinsic value of the stock warrants in the table above is $46,646 and $0 at December 31, 2013 and 2012, respectively. The aggregate intrinsic value is before applicable income taxes and is calculated based on the difference between the exercise price of the warrants and the estimated fair market value of the Company's common stock as of the respective dates.

Stockholders_Equity_Deficit

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity (Deficit) [Abstract]	'
Stockholders' Equity (Deficit)	'
	12
	Stockholders' Equity (Deficit)
	Authorized Capital
	Heat has authorized 112,500 shares of Series 1 Preferred Stock (par value $0.0001) as of December 31, 2013 and 2012. Of the Series 1 Preferred Stock, 112,500 were issued and outstanding as of December 31, 2012. No Series 1 Preferred Stock was outstanding at December 31, 2013. Heat has authorized 2,000,000 shares of Series A Preferred Stock (par value $0.0001) as of December 31, 2013 and 2012. Of the Series A Preferred Stock, 1,863,128 shares were issued and outstanding as of December 31, 2012. No Series A Preferred Stock was outstanding at December 31, 2013. In 2013, Heat authorized 4,100,000 shares of Series B Preferred Stock (par value $0.0002). In March 2013, the Company sold an aggregate of 1,891,419 shares of the Company's Series B-1 Preferred Stock for gross proceeds of approximately $5.0 million in our Series B Preferred Stock private placement. All shares of the Series B Preferred Stock, together with accrued dividends, automatically converted into shares of the Company's common stock upon the consummation of the Company's initial public offering on July 29, 2013.
	Heat had 50,000,000 shares of common stock (par value $0.0002) authorized as of December 31, 2013 and 2012. Of the 50,000,000 common stock shares, 6,375,426 and 2,144,542 were issued and 6,375,426 and 1,858,971 were outstanding as December 31, 2013 and 2012, respectively.
	Preferred Stock
	Series 1, Series A, Series B-1, and Series B-2
	Automatic Conversion
	Each share of Preferred Stock automatically converts to common stock upon the earlier to occur of (i) on the date of consummation of a sale of common stock in a firm commitment underwritten public offering resulting in aggregate net cash proceeds to the Company (after deducting applicable underwriting discounts and commissions) of at least $15 million net proceeds; (ii) with respect to the Series A Preferred Stock, if 2/3 of the Series A Preferred Stock holders (including one of the larger investors so long as they hold 40% of the Series A Preferred Stock) vote in favor of a conversion then the Series A will automatically convert to common stock; (iii) with respect to the Series 1 Preferred Stock, if 2/3 of the Series 1 Preferred Stock holders vote in favor of a conversion then the Series 1 will automatically convert to common stock; and (iv) with respect to the Series B Preferred Stock if 2/3 of the Series B Preferred Stock holders vote in favor of a conversion then the Series B will automatically convert to common stock. As a result of the IPO, all outstanding shares of preferred stock were automatically converted to common stock.
	Optional Conversion
	The preferred stock is convertible into common stock at the option of the holder at any time. The conversion ratio for each share of the Series 1 Preferred Stock and the Series A Preferred Stock was its Original Issue Price ($2.35 and $2.10 for each share of the Series 1 Preferred Stock and Series A Preferred Stock, respectively) divided by its Conversion Price, as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like, which Conversion Price initially was the Original Issue Price. The conversion ratio for each share of the Series B-1 Preferred Stock and the Series B-2 Preferred Stock was its Original Issue Price ($2.67 and $5.00 for each share of the Series B-1 Preferred Stock and Series B-2 Preferred Stock, respectively) plus accrued but unpaid dividends thereon divided by its conversion price, as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like, which conversion price initially was the Original Issue Price. As a result of the 1-for-2.3 reverse stock split, the conversion ratio for the Preferred Stock was 0.4348.
	In the event the Company at any time or from time to time after the Initial Series B Issuance Date shall issue additional shares of common stock without consideration or for consideration per share less than the Series 1 Conversion Price, Series A Conversion Price, Series B-1 Conversion Price, or Series B-2 Conversion Price, in effect on the date of and immediately prior to such issue, then the Series 1 Conversion Price, Series A Conversion Price, the Series B-1 Conversion Price, Series B-2 Conversion Price, shall be reduced, to a price determined by multiplying the Series 1 Conversion Price, Series A Conversion Price, the Series B-1 Conversion Price, or the Series B-2 Conversion Price in effect by a fraction, (A) the numerator of which shall be the number of shares of common stock outstanding immediately prior to such issuance, on a fully-diluted basis, plus the number of shares of common stock which the aggregate consideration received by the Company for the total number of Additional Shares of Common Stock so issued would purchase at the Series 1 Conversion Price, Series A Conversion Price, the Series B-1 Conversion Price, or the Series B-2 Conversion Price, as in effect immediately prior to such issuance, and (B) the denominator of which shall be the number of shares of common stock outstanding immediately prior to such issuance, on a fully-diluted basis, plus the number of such Additional Shares of common stock so issued. As a result of the IPO, all outstanding shares of preferred stock were automatically converted to common stock.
	The preferred stock was determined to have characteristics more akin to equity than debt. Particularly, the preferred stock had no mandatory redemption provision nor was it redeemable at the option of the holder. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore did not need to be bifurcated and classified as a liability.
	Dividends
	The Series B Preferred Stock has a priority with respect to dividend distributions and distributions upon liquidation. The Series B Preferred Stock receive dividends when and as and if declared by the Board at a rate of 5% of their original issue price of such shares which is $6.14 per share for the Series B-1 Preferred Stock and $11.50 per share for the Series B-2 Preferred Stock. If the Company declares or pays a dividend upon the common stock, they must also pay to the holders of the Series A, 1 and B Preferred Stock the dividends that would have been declared with respect to common stock issuable upon conversion of the Series A, 1 and B Preferred Stock; provided, however that the Company cannot declare or pay a dividend unless and until all accrued dividends on the Series B Preferred Stock have been paid.
	Liquidation
	In the event of a liquidation, the holders of the Series B-1 and B-2 Preferred Stock are entitled to receive before any payment to any other Preferred Stockholder or common stock holder and pari passu with the holders of the Series 1 Preferred Stock an amount per share equal to the greater of $6.14 for the Series B-1 Preferred Stock and $11.50 for the Series B-2 Preferred Stock plus any dividends accrued and unpaid whether or not declared. After payment in full of the Series B Preferred Stockholders the holders of the Series A Preferred Stock are entitled to receive before any payment to the common stock holder and pari passu with the holders of the Series 1 Preferred Stock an amount per share equal to $4.83 plus any dividends declared but unpaid. In the event of a liquidation, the holders of the Series 1 Preferred Stock are entitled to receive before any payment to the common stock holder and pari passu with any distribution to the Series A Preferred Stock an amount per share equal to $5.41 plus any dividends declared but unpaid. After the payment in full of the amounts set forth above, the Company's assets will be distributed ratably to all holders of common stock and Series B Preferred Stock on an as converted basis except that the Series B Preferred Stockholders shall not continue to share in such distribution after each has received 3 times its Original Issue Price.
	Voting Rights
	Each holder of Preferred Stock is entitled to vote on all matters stockholders are entitled to vote and to cast the number of votes as shall equal the whole number of shares of common stock into which their shares of Preferred Stock are convertible.
	Preferred Stock Dividend
	In March 2013, the Company sold an aggregate of 1,891,419 shares of the Company's Series B-1 Preferred Stock for gross proceeds of approximately $5.0 million in our Series B Preferred Stock private placement. All shares of the Series B Preferred Stock, together with accrued dividends, automatically converted into shares of the Company's common stock upon the consummation of the Company's initial public offering on July 29, 2013. In addition, the investors in the Series B-1 Preferred Stock were issued shares of the Company's common stock having a value based upon the initial public offering price of $361,668 and the Company's obligation to issue, and the investors, obligation to purchase, Series B-2 Preferred Stock and warrants upon fulfillment of certain conditions specified in the Company's stock purchase agreement dated as of March 25, 2013 entered into in connection with such private placement (the "Stock Purchase Agreement") terminated. The issuance of common stock to the Series B-1 Preferred stockholders totaling $361,668 has been accounted for as a preferred stock dividend, and as a result, has been included as an expense attributable to common stockholders in the Company's condensed consolidated statements of operations.
	Initial Public Offering
	On July 29, 2013, the Company sold 2,500,000 shares of common stock at a public offering price of $10.00 per share upon the closing of the Company's initial public offering ("IPO") with gross proceeds of $25 million and net proceeds of $22.4 million. On August 15, 2013, the Company sold an additional 100,000 shares of common stock at a public offering price of $10.00 per share pursuant to the partial exercise of the over-allotment option granted to the underwriters resulting in additional gross proceeds to the Company of $1,000,000 and additional net proceeds of $930,000. On September 6, 2013, the Company sold an additional 100,000 shares of common stock at a public offering price of $10.00 per share pursuant to the partial exercise of the over-allotment option granted to the underwriters resulting in additional gross proceeds to the Company of $1,000,000 and additional net proceeds of $930,000. The total gross proceeds raised from the offering and over-allotment option were $27,000,000, before underwriting discounts, commissions and other offering expenses payable by the Company. The total net proceeds from the offering were approximately $24.3 million. Upon the closing of the IPO, all shares of the Company's then-outstanding preferred stock automatically converted into an aggregate of 1,696,683 shares of common stock. In addition, upon the closing of the IPO, the Company issued an additional 36,167 shares of common stock to the Series B Preferred Stockholders as a Preferred Stock dividend. This transaction is discussed above under "Preferred Stock Dividend". At that time, the Company's obligation to issue, and the Series B Preferred Stockholders' obligation to purchase Series B-2 Preferred Stock under the Stock Purchase Agreement terminated.
	Restricted Stock
	A summary of the Company's unvested restricted stock activity as of December 31, 2013 is as follows:
		Shares			Weighted-
					Average
					Fair Value
	Unvested at December 31, 2012		2,899		$	2.23
	Vested		(2,899	)	$	8.81
	Unvested at December 31, 2013		-		$	-
	As of December 31, 2013, all restricted stock has vested and accordingly all stock-based compensation expense related to vested restricted stock has been recognized.
	Common Stock Warrants
	There are 20,549 warrants outstanding that are convertible into common stock that have an exercise price of $4.83 per share and expire 10 years from the date of issuance. These warrants were issued to lenders and were originally exercisable into Series A Preferred stock. The warrants converted from preferred stock warrants into warrants to purchase common stock upon the completion of the initial public offering in July 2013. However, since the warrants still have an anti-dilution provision, they remain liabilities and are subject to re-measurement at each balance sheet date. Refer to Footnote 11.
	On March 10, 2011, the Company issued warrants to purchase 32,610 shares of common stock to non-employee placement agents in consideration for a private equity placement transaction. The warrants have an exercise price of $0.48 per share and expire 10 years from the issuance date. These warrants do not meet the criteria required to be classified as liability awards and therefore they are treated as equity awards.
	In connection with our initial public offering, the Company issued warrants to the underwriters for 125,000 shares of common stock issuable at $12.50 per share upon exercise. The warrants have a ten-year life and expire on July 29, 2023. These warrants do not meet the criteria required to be classified as liability awards and therefore they are treated as equity awards.
	The following table summarizes the activity of the Company's common stock warrants, retro actively adjusted for the 1-for-2.3 reverse stock split.
		Common Stock
		Warrants
	Outstanding, January 1, 2012		45,550
	Granted		7,609
	Exercised		-
	Expired		-
	Outstanding, December 31, 2012		53,159
	Granted to underwriters		125,000
	Exercised		-
	Expired		-
	Outstanding, December 31, 2013		178,159
	Equity Compensation Plan
	2009 Stock Incentive Plan
	In 2009, the Company adopted the 2009 Stock Option Plan of Heat Biologics, Inc. (the "2009 Plan"), under which stock options to acquire 500,000 common shares could be granted to key employees, directors, and independent contractors.  Under the 2009 Plan, both incentive and non-qualified stock options could be granted under terms and conditions established by the Board of Directors. The exercise price for incentive stock options was the fair market value of the related common stock on the date the stock option was granted. Stock options granted under the 2009 Plan generally have terms of 10 years and have various vesting schedules.
	The Company amended the 2009 Stock Option Plan and all related addendum agreements in April 2011. This second amendment increased the number of shares available for issuance from 500,000 to 1,500,000. As of December 31, 2013 and 2012, there were 633,482 and 590,047 and stock options outstanding under the 2009 Plan, respectively.
	The following table summarizes the components of the Company's stock-based compensation included in net loss:
		December 31,
		2013			2012
	Employee stock options	$	131,178		$	60,956
	Non-employee stock options		415,212			128,157
	Restricted stock awards		25,534			28,783
		$	571,924		$	217,896
	Stock Options
	The fair value of each stock option is estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions for stock options granted during the years ended December 31, 2013 and 2012:
		December 31,
		2013			2012
Dividend yield		0.00%			0.00%
Expected volatility		90-112%			80-90%
Risk-free interest rate		1.39-2.26%			0.72-0.97%
Expected lives (years)		5.75-6.5			5-6.25
The risk-free interest rate is based on U.S. Treasury interest rates at the time of the grant whose term is consistent with the expected life of the stock options. The Company used an average historical stock price volatility based on an analysis of reported data for a peer group of comparable companies that have issued stock options with substantially similar terms, as the Company did not have any trading history for its common stock. Expected term represents the period that the Company's stock option grants are expected to be outstanding. The Company elected to utilize the "simplified" method to value stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.
Expected dividend yield was considered to be 0% in the option pricing formula since the Company had not paid any dividends and had no plans to do so in the future. The forfeiture rate was considered to be none insofar as the historical experience of the Company is very limited. As required by ASC 718, the Company will adjust the estimated forfeiture rate based upon actual experience.
The Company recognized $571,924 and $217,896 in stock-based compensation expense for the years ended December 31, 2013 and 2012, respectively for the Company's stock option awards.
The following tables summarize the stock option activity for the years ended December 31, 2012 and 2013:
	Shares			Weighted
				Average
				Exercise
				Price
Outstanding, January 1, 2012		471,905		$	0.64
Granted		178,742		$	0.76
Exercised		(22,827	)	$	0.51
Expired/Cancelled		(37,773	)	$	0.02
Outstanding, December 31, 2012		590,047		$	0.71
Granted		186,736		$	10.07
Exercised		(80,706	)	$	0.67
Expired/Cancelled		(62,595	)	$	1.96
Outstanding, December 31, 2013		633,482		$	3.36
The weighted average grant-date fair value of stock options granted during the years ended December 31, 2013 and 2012 was $8.51 and $1.31, respectively.
The total fair value of stock options that vested during the year ended December 31, 2013 was approximately $440,820.
The following table summarizes information about stock options outstanding at December 31, 2013:
Options Outstanding						Options Exercisable			Options Vested or Expected to Vest
Balance		Weighted		Weighted		Balance	Weighted	Weighted	Balance	Weighted	Weighted
as of		Average		Average		as of	Average	Average	as of	Average	Average
12/31/13		Remaining		Exercise		12/312013	Remaining	Exercise	12/31/13	Remaining	Exercise
		Contractual		Price			Contractual	Price		Contractual	Price
		Life					Life			Life
		(Years)					(Years)			(Years)
633,482		7.27		$3.36		426,423	6.31	$1.23	426,423	6.31	$1.23
As of December 31, 2013, the unrecognized stock-based compensation expense related to unvested stock options was approximately $1,604,200 that is expected to be recognized over a weighted average period of approximately 14 months.
A summary of the activity of the Company's unvested stock options is as follows:
	Shares			Weighted
				Average
				Exercise
				Price
Balance, January 1, 2012		248,439		$	0.64
Granted		178,742		$	0.76
Vested		(257,510	)	$	0.51
Forfeited		(11,594	)	$	0.02
Outstanding, December 31, 2012		158,077		$	0.71
Granted		186,736		$	10.07
Vested		-91,020		$	0.67
Forfeited		(46,734	)	$	1.96
Outstanding, December 31, 2013		207,059		$	3.36

Income_Tax

Income Tax	12 Months Ended
	Dec. 31, 2013
Income Tax [Abstract]	'
Income Tax	'
	13
	Income Tax
	The components of income tax expense (benefit) attributable to continuing operations are as follows:
		Year ended December 31,
		2013			2012
	Current expense:
	Federal	$	-		$	-
	State		-			-
	Deferred expense (benefit):
	Federal	$	-		$	-
	State		-			-
	Total	$	-		$	-
	The differences between the Company's consolidated income tax expense attributable to continuing operations and the expense computed at the 34% United States statutory income tax rate were as follows:
		Year ended December 31,
		2013			2012
	Federal income tax expense at statutory rate	$	(2,247,353	)	$	(840,190	)
	State and local income taxes, net of federal benefit		(186,475	)		(105,170	)
	Non-deductible expenses		4,985			54,991
	Prior-period true-up		162,061			(152,306	)
	Research & development credit		(180,687	)		(57,293	)
	Change in tax rate		32,774			-
	Increase in valuation allowance		2,414,695			1,099,968
		$	-		$	-
	The income tax effects of temporary differences from continuing operations that give rise to significant portions of deferred income tax assets (liabilities) are presented below:
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryforward	$	4,167,785		$	2,186,432
	Research & development credit		424,739			189,350
	Other		247,966			50,013
	Valuation allowance		(4,840,490	)		(2,425,795	)
	Deferred income taxes	$	-		$	-
	During 2013, the Company's valuation allowance increased by $2,414,695. This increase was primarily due to the generation of additional net operating loss carryforwards and income tax credits.
	The Company has approximately $20,999,761 of federal and state operating loss carryforwards which begin to expire in 2023.
	In accordance with FASB ASC 740, Accounting for Income Taxes, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2013, the Company had no unrecognized income tax benefits and correspondingly there is no impact on the Company's effective income tax rate associated with these items. The Company's policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying statements of income. As of December 31, 2013 and 2012, the Company had no such accruals.
	The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to examination by taxing authorities for the tax years ended December 31, 2008 through 2012.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	14
	Commitments and Contingencies
	In November 2011, the Company entered into a thirteen-month lease agreement for office space commencing on January 1, 2012. The monthly base rent is $3,870, which commenced February 1, 2012. On December 19, 2012, we entered into a lease modification agreement that extended the lease term and increased the monthly rent to $4,046. The Company will remain in the office space on a month to month basis until new office space is available.
	In connection with the convertible note agreement entered into on October 20, 2011 with a vendor for an amount up to $950,000, the Company is required to use the vendor exclusively for the manufacture and supply of the material for the Company's Phase III clinical trials and commercialization efforts. This note is no longer outstanding as of December 31, 2013.

Related_Party

Related Party	12 Months Ended
	Dec. 31, 2013
Related Party [Abstract]	'
Related Party	'
	15
	Related Party
	The Chairman of the Company's Scientific Advisory Board was paid $0, $18,750 and $140,625 in consulting fees for the years ended December 31, 2013 and 2012 and the period from inception through December 31, 2013, respectively.
	A member of the Company's Scientific Advisory Board was paid $0 for the years ended December 31, 2013 and 2012, respectively. The consulting fees paid since inception was $50,000.
	A member of the Company's management was paid $34,480, $30,910, and $70,910 in consulting fees for the years ended December 31, 2013 and 2012 and the period from inception through December 31, 2013, respectively.
	The Company paid three members of the Clinical Advisory Board for consulting during 2013. These members received $45,000, $16,590 and $14,700 for their services during the year ended December 31, 2013. These members were not paid prior to 2013.
	The Company compensates its board members. Board members received between $5,000 and $10,870 for services rendered during 2013. Board members were not compensated prior to the Company's initial public offering in 2013.
	The Company had a related party payable balance of $13,000 and $0 as of December 31, 2013 and 2012, respectively.
	In June 2012, the Company sold its 92.5% ownership interest in Heat II to a related party in exchange for $9,250 in cash and a receivable of $296,224 to be paid in full in seven years from the date of the purchase. Interest accrues on the receivable at a rate of 6% per annum. At December 31, 2012, the Company also has a related party receivable from this entity for $9,571 related to invoices received by the Company pertaining to expenses of Heat II incurred subsequent to the sale of Heat II.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Net Loss Per Share [Abstract]	'
Net Loss Per Share	'
	16
	Net Loss Per Share
	Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options that are computed using the treasury stock method.
	For the years ended December 31, 2013 and 2012, all of the Company's common stock options and warrants, preferred stock, and preferred stock warrants are anti-dilutive and therefore have been excluded from the diluted calculation.
	The following table reconciles net loss to net loss applicable to common shareholders:
		For the year ended
		December 31,
		2013			2012
	Net loss	$	(6,609,864	)	$	(2,471,147	)
	Net loss: Non-controlling interest		(198,516	)		(50,947	)
	Beneficial conversion charge		(2,300,000	)		-
	Preferred Stock Dividend		(361,668	)		-
	Net loss applicable to common stockholders	$	(9,073,016	)	$	(2,420,200	)
	Weighted-average number of common shares used in net loss per share applicable to common stockholders-basic and diluted		3,747,357			1,831,769
	Net loss per share applicable to common stockholders-basic and diluted	$	(2.42	)	$	(1.32	)
	The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect):
			For the year ended
			December 31,
			2013			2012
	Preferred stock (on an as converted basis)			-			860,017
	Preferred stock warrants			-			20,549
	Outstanding stock options			633,482			590,047
	Unvested restricted stock			-			2,899
	Common stock warrants			53,159			32,610
	Reverse Stock Split
	In May 2013, the Company's board of directors and stockholders approved a 1-for-2.3 reverse stock split of the Company's common stock. The reverse stock split became effective on May 29, 2013. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the increase in par value to additional paid-in capital.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	17
	Subsequent Events
	In the first quarter of 2014, the Company entered into a lease agreement to lease a new office facility. The new lease commences on or around May 1, 2014 and includes escalating rent payments and a sixty-month term. Rent expense will be recorded on a straight-line basis over the lease term.
	Future minimum lease payments are as follows:
	2014	$	82,353
	2015		183,137
	2016		188,631
	2017		194,290
	2018		200,119
	Total	$	848,530
	Total rent expense for the years ended December 31, 2013 and 2012 was $48,377 and $43,341, respectively.
	In March 2014, the subsidiary, Heat Biologics I, Inc. entered into an additional exclusive license agreement with the University of Miami. No annual payments are required under this license agreement.  The Company is obligated to make milestone payments under this license agreement as follows: $50,000 upon completion of a phase I clinical trial, $100,000 upon completion of a phase II trial, $100,000 upon completion of a phase III trial, and $100,000 upon acceptance of a BLA by the FDA or its foreign equivalent.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Summary of Significant Accounting Policies [Abstract]

'

Basis of Accounting

'

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Activities during the development stage include developing the business plan, raising capital, and developing the Company's platform technology.

Principles of Consolidation

'

Principles of Consolidation

The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. ("Heat I") and Heat Biologics II, Inc. ("Heat II"), Heat Biologics III, Inc. ("Heat III"), Heat Biologics IV, Inc. ("Heat IV") and Heat Biologics GmbH. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2013 and 2012, Heat held a 92.5% controlling interest in Heat I and accounts for its less than 100% interest in the consolidated financial statements in accordance with U.S. GAAP. Accordingly, the Company presents non-controlling interests as a component of stockholders' equity (deficit) on its consolidated balance sheets and reports non-controlling interest net loss under the heading "net loss - non-controlling interest" in the consolidated statements of operations. In June 2012, the Company sold its entire 92.5% interest in Heat II. The operations of Heat II through June 25, 2012, and inception to date, are presented in the accompanying consolidated statements of operations as a loss from discontinued operations.

Use of Estimates

'

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, income taxes and stock-based compensation. Actual results may differ from those estimates.

Cash and Cash Equivalents and Restricted Cash

'

Cash and Cash Equivalents and Restricted Cash

The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $1,252 and $26,214 at December 31, 2013 and 2012, respectively. The United States Patent and Trade Office ("USPTO") requires the Company to maintain an account with a minimum of $1,000 to be used to pay fees associated with new trademarks of the Company and one of the Company's lenders required a minimum $25,000 cash balance to be maintained with the lending bank during 2012.

Concentration of Credit Risk

'

Concentration of Credit Risk

At times, cash balances may exceed the Federal Deposit Insurance Corporation ("FDIC") insurable limits. The Company has never experienced any losses related to these balances. All of the Company's cash balances were fully insured at December 31, 2012. As of December 31, 2013, cash amounts in excess of $250,000 were not fully insured. The uninsured cash balance as of December 31, 2013 was $4,046,451. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.

Debt Issuance Costs, net

'

Debt Issuance Costs, net

Debt issuance costs include the costs incurred to obtain financing, including the fair value of preferred stock warrants at the date of their issuance, and are amortized using the straight-line method, which approximates the effective interest method, over the life of the related debt. Debt issuance costs are included in the accompanying consolidated balance sheets net of amortization.

Property and Equipment

'

Property and Equipment

Property and equipment are stated at cost and are capitalized if the cost exceeds $500. Depreciation is calculated using the straight-line method and is based on estimated useful lives of 3 years for computer equipment and seven years for furniture and fixtures.

Stock Warrants Liability

'

Stock Warrants Liability

In December 2011 and August 2012, the Company entered into a promissory note with each of two lenders and issued preferred stock warrants to each lender as consideration. The Company has accounted for these freestanding warrants as liabilities at their fair value on the accompanying consolidated balance sheets. The warrants are subject to re-measurement at each balance sheet date, and the change in fair value, if any, is recognized as other income (expense). The warrants converted from preferred stock warrants into warrants to purchase common stock upon the completion of the initial public offering in July 2013 and the number of shares were adjusted for the 1-for-2.3 reverse stock split. However, since the warrants still have an anti-dilution provision, they remain liabilities and are subject to re-measurement at each balance sheet date. The warrants are valued using a Monte Carlo simulation which is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company's future expected stock prices and minimizes standard error.

Significant assumptions used in the valuation of the stock warrants liability were as follows:

December 31,

2013

2012

Exercise price

$

4.83

$

4.83

Risk-free interest rate

2.75

%

1.78

%

Expected volatility

71.6-71.9

%

75.6-76.3

%

Expected life (years)

7.96-8.6

10

Expected dividend yield

0

%

0

%

Beneficial Conversion Feature

'

Beneficial Conversion Feature

When the Company issues an equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Company's common stock and the effective conversion price of the equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the equity.

The amount allocated to the beneficial conversion feature is presented as an immediate charge to earnings available to common shareholders for convertible preferred stock instruments that are convertible by the shareholders at any time. In connection with the Company's issuance of Series B-1 Preferred Stock during fiscal year 2013, the Company recorded a beneficial conversion charge of $2.3 million representing the difference between the effective conversion price of $6.14 and the fair value of the Company's common stock as of the Commitment Date of $8.81.

Net Loss per Share

'

Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation.

Fair Value of Financial Instruments

'

Fair Value of Financial Instruments

The carrying amount of certain of the Company's financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, deposits, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. The carrying value of the Company's notes payable and convertible notes payable at December 31, 2012 approximated fair value because the interest rates under those obligations approximated market rates of interest available to the Company for similar instruments.

As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level I - Observable inputs such as quoted prices in active markets for identical assets or liabilities.

Level II - Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level III - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's financial instruments that are measured at fair value on a recurring basis consist only of the stock warrants liability. The Company's stock warrants liability was classified within Level III of the fair value hierarchy and as of December 31, 2013 and 2012.

The change in the fair value of the Level III warrants liability is summarized below:

Fair value at December 31, 2012

$

92,150

Issuances

-

Change in fair value during the period

30,440

Fair value at December 31, 2013

$

122,590

The change in the fair value of the Level III stock warrants liability is summarized below:

31-Dec-13

Identical

Observable

Unobservable

Total

Assets

Inputs

Inputs

December 31,

Description

(Level 1)

(Level 2)

(Level 3)

2013

Liabilities measured at fair value

Stock Warrant Liability

$

-

$

-

$

(122,590

)

$

(122,590

)

Total Liabilities measured at fair value

$

-

$

-

$

(122,590

)

$

(122,590

)

31-Dec-12

Identical

Observable

Unobservable

Total

Assets

Inputs

Inputs

December 31,

Description

(Level 1)

(Level 2)

(Level 3)

2012

Liabilities measured at fair value

Stock Warrant Liability

$

-

$

-

$

(92,150

)

$

(92,150

)

Total Liabilities measured at fair value

$

-

$

-

$

(92,150

)

$

(92,150

)

Marketing

'

Marketing

Marketing costs are expensed as incurred. Marketing expense totaled $135,366 and $5,921 for the years ended December 31, 2013 and 2012, respectively. Marketing expenses from inception through December 31, 2013 totaled $183,274.

Income Tax

'

Income Tax

Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

In accordance with FASB ASC 740, Accounting for Income Taxes, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2013 and 2012, the Company had no unrecognized income tax benefits and correspondingly there is no impact on the Company's effective income tax rate associated with these items. The Company's policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations, As of December 31, 2013 and 2012, the Company had no such accruals.

Stock-Based Compensation

'

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model.

Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2013 and 2012 represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received.

Net loss attributable to non-controlling interests

'

Net loss attributable to non-controlling interests

Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. The Company's net loss attributable to non-controlling interests relates to the University's ownership in Heat I, and its ownership interest in Heat II before the divestiture of Heat II on June 25, 2012.

Revenue Recognition

'

Revenue Recognition

The Company recognizes government grants when there is reasonable assurance that they will comply with the conditions attached to the grants and the grants will be received. The grants are recognized using an income approach and grant revenue is recognized as the related expenses are incurred.

Research and Development

'

Research and Development

Research and development costs are expensed as incurred. The Company has acquired exclusive licensing rights to intellectual property to further its research and development. These costs are expensed as incurred. The Company also incurs legal costs relating to the filing and application fees for patents which are owned by the universities with which the Company has license agreements. These costs are also expensed as research and development expense as incurred.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Schedule of Significant Assumptions Used in Valuing Stock Warrants Liability	'
	Significant assumptions used in the valuation of the stock warrants liability were as follows:
		December 31,
		2013				2012
	Exercise price	$	4.83			$	4.83
	Risk-free interest rate		2.75	%			1.78	%
	Expected volatility		71.6-71.9	%			75.6-76.3	%
	Expected life (years)		7.96-8.6				10
	Expected dividend yield		0	%			0	%
Schedule of Change in Fair Value of Level III Warrants Liability	'
	The change in the fair value of the Level III warrants liability is summarized below:
	Fair value at December 31, 2012	$	92,150
	Issuances		-
	Change in fair value during the period		30,440
	Fair value at December 31, 2013	$	122,590
Schedule of Change in Fair Value of the Level III Common Stock Warrant Liability	'
	The change in the fair value of the Level III stock warrants liability is summarized below:
		31-Dec-13
		Identical			Observable			Unobservable			Total
		Assets			Inputs			Inputs			December 31,
	Description	(Level 1)			(Level 2)			(Level 3)			2013
	Liabilities measured at fair value
	Stock Warrant Liability	$	-		$	-		$	(122,590	)	$	(122,590	)
	Total Liabilities measured at fair value	$	-		$	-		$	(122,590	)	$	(122,590	)
		31-Dec-12
		Identical			Observable			Unobservable			Total
		Assets			Inputs			Inputs			December 31,
	Description	(Level 1)			(Level 2)			(Level 3)			2012
	Liabilities measured at fair value
	Stock Warrant Liability	$	-		$	-		$	(92,150	)	$	(92,150	)
	Total Liabilities measured at fair value	$	-		$	-		$	(92,150	)	$	(92,150	)

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments [Abstract]	'
Schedule of Held-To-Maturity Investments Estimated Fair Value of Investments	'
	The maturities of held-to-maturity investments at December 31, 2013 were as follows:
		Less than		Total
		1 Year
	Certificates of deposit, commercial paper	$	17,297,165	$	17,297,165
Schedule of Maturities of Held-To-Maturity Investments	'
	The maturities of held-to-maturity investments at December 31, 2013 were as follows:
		Less than		Total
		1 Year
	Certificates of deposit, commercial paper	$	17,297,165	$	17,297,165

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	Property and equipment consisted of the following:
		December 31,
		2013			2012
	Furniture and fixtures	$	10,780		$	10,780
	Computers		13,175			3,213
	Lab equipment		39,357			-
	Total		63,312			13,993
	Accumulated depreciation		(9,559	)		(3,211	)
	Property and equipment, net	$	53,753		$	10,782

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses [Abstract]	'
Schedule of Accrued Expenses	'
	Accrued expenses consist of the following:
		December 31,
		2013		2012
	Compensation and related benefits	$	356,588	$	105,927
	Accrued patent fees		40,000		20,000
	Miscellaneous expenses		106,462		3,281
		$	503,050	$	129,208

License_Agreements_Tables

License Agreements (Tables)	12 Months Ended
	Dec. 31, 2013
License Agreements [Abstract]	'
Schedule of Future Minimum Royalty Payments	'
	Future minimum royalty payments as of December 31, 2013 are as follows:
	Year ended December 31,
	2014	$	30,000
	2015		30,000
	2016		30,000
	2017		280,000
	2018		30,000
	Thereafter		120,000
	Total	$	520,000

Stock_Warrants_Liability_Table

Stock Warrants Liability (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Warrants Liability [Abstract]	'
Summary of Stock Warrants Liability Activity	'
	The summary of stock warrants liability activity for the years ended December 31, 2013 and 2012 is as follows:
		Number of		Weighted		Weighted		Weighted
		Warrants		Average		Average		Average
				Exercise		Remaining		Grant
				Price		Contractual		Date
						Life (in years)		Fair Value
	Outstanding at December 31, 2011		12,940	$	4.83		9.9	$	1.91
	Granted		7,609	$	4.83		9.9	$	1.81
	Exercised		-		-		-		-
	Expired/cancelled		-		-		-		-
	Outstanding at December 31, 2012		20,549	$	4.83		8.9	$	1.64
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired/cancelled		-		-		-		-
	Outstanding at December 31, 2013		20,549	$	4.83		8.2	$	5.95

Stockholders_Equity_Deficit_Ta

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity (Deficit) [Abstract]	'
Schedule of Unvested Restricted Stock Activity	'
	A summary of the Company's unvested restricted stock activity as of December 31, 2013 is as follows:
		Shares			Weighted-
					Average
					Fair Value
	Unvested at December 31, 2012		2,899		$	2.23
	Vested		(2,899	)	$	8.81
	Unvested at December 31, 2013		-		$	-
Summary of Activity of Common Stock Warrants Retroactively Adjusted for Reverse Stock Split	'
	The following table summarizes the activity of the Company's common stock warrants, retro actively adjusted for the 1-for-2.3 reverse stock split.
		Common Stock
		Warrants
	Outstanding, January 1, 2012		45,550
	Granted		7,609
	Exercised		-
	Expired		-
	Outstanding, December 31, 2012		53,159
	Granted to underwriters		125,000
	Exercised		-
	Expired		-
	Outstanding, December 31, 2013		178,159
Schedule of Components of Stock-based Compensation Included in Net Loss	'
	The following table summarizes the components of the Company's stock-based compensation included in net loss:
		December 31,
		2013			2012
	Employee stock options	$	131,178		$	60,956
	Non-employee stock options		415,212			128,157
	Restricted stock awards		25,534			28,783
		$	571,924		$	217,896
Schedule of Stock Option Valuation Assumptions	'
	The fair value of each stock option is estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions for stock options granted during the years ended December 31, 2013 and 2012:
		December 31,
		2013			2012
	Dividend yield		0.00%			0.00%
	Expected volatility		90-112%			80-90%
	Risk-free interest rate		1.39-2.26%			0.72-0.97%
	Expected lives (years)		5.75-6.5			5-6.25
Schedule of Stock Option Activity	'
	The following tables summarize the stock option activity for the years ended December 31, 2012 and 2013:
		Shares			Weighted
					Average
					Exercise
					Price
	Outstanding, January 1, 2012		471,905		$	0.64
	Granted		178,742		$	0.76
	Exercised		(22,827	)	$	0.51
	Expired/Cancelled		(37,773	)	$	0.02
	Outstanding, December 31, 2012		590,047		$	0.71
	Granted		186,736		$	10.07
	Exercised		(80,706	)	$	0.67
	Expired/Cancelled		(62,595	)	$	1.96
	Outstanding, December 31, 2013		633,482		$	3.36
Schedule of Options Outstanding, Exercisable, and Vested or Expected to Vest	'
	The following table summarizes information about stock options outstanding at December 31, 2013:
	Options Outstanding						Options Exercisable			Options Vested or Expected to Vest
	Balance		Weighted		Weighted		Balance	Weighted	Weighted	Balance	Weighted	Weighted
	as of		Average		Average		as of	Average	Average	as of	Average	Average
	12/31/13		Remaining		Exercise		12/312013	Remaining	Exercise	12/31/13	Remaining	Exercise
			Contractual		Price			Contractual	Price		Contractual	Price
			Life					Life			Life
			(Years)					(Years)			(Years)
	633,482		7.27		$3.36		426,423	6.31	$1.23	426,423	6.31	$1.23
Summary of Unvested Stock Options	'
	A summary of the activity of the Company's unvested stock options is as follows:
		Shares			Weighted
					Average
					Exercise
					Price
	Balance, January 1, 2012		248,439		$	0.64
	Granted		178,742		$	0.76
	Vested		(257,510	)	$	0.51
	Forfeited		(11,594	)	$	0.02
	Outstanding, December 31, 2012		158,077		$	0.71
	Granted		186,736		$	10.07
	Vested		-91,020		$	0.67
	Forfeited		(46,734	)	$	1.96
	Outstanding, December 31, 2013		207,059		$	3.36

Income_Tax_Tables

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax [Abstract]	'
Schedule of Components of Income Tax Expense	'
	The components of income tax expense (benefit) attributable to continuing operations are as follows:
		Year ended December 31,
		2013			2012
	Current expense:
	Federal	$	-		$	-
	State		-			-
	Deferred expense (benefit):
	Federal	$	-		$	-
	State		-			-
	Total	$	-		$	-
Schedule of Income Tax Rate Reconciliation	'
	The differences between the Company's consolidated income tax expense attributable to continuing operations and the expense computed at the 34% United States statutory income tax rate were as follows:
		Year ended December 31,
		2013			2012
	Federal income tax expense at statutory rate	$	(2,247,353	)	$	(840,190	)
	State and local income taxes, net of federal benefit		(186,475	)		(105,170	)
	Non-deductible expenses		4,985			54,991
	Prior-period true-up		162,061			(152,306	)
	Research & development credit		(180,687	)		(57,293	)
	Change in tax rate		32,774			-
	Increase in valuation allowance		2,414,695			1,099,968
		$	-		$	-
Schedule of Deferred Tax Assets and Liabilities	'
	The income tax effects of temporary differences from continuing operations that give rise to significant portions of deferred income tax assets (liabilities) are presented below:
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryforward	$	4,167,785		$	2,186,432
	Research & development credit		424,739			189,350
	Other		247,966			50,013
	Valuation allowance		(4,840,490	)		(2,425,795	)
	Deferred income taxes	$	-		$	-

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Net Loss Per Share [Abstract]	'
Schedule of Net Loss Per Share	'
	The following table reconciles net loss to net loss applicable to common shareholders:
		For the year ended
		December 31,
		2013			2012
	Net loss	$	(6,609,864	)	$	(2,471,147	)
	Net loss: Non-controlling interest		(198,516	)		(50,947	)
	Beneficial conversion charge		(2,300,000	)		-
	Preferred Stock Dividend		(361,668	)		-
	Net loss applicable to common stockholders	$	(9,073,016	)	$	(2,420,200	)
	Weighted-average number of common shares used in net loss per share applicable to common stockholders-basic and diluted		3,747,357			1,831,769
	Net loss per share applicable to common stockholders-basic and diluted	$	(2.42	)	$	(1.32	)
Schedule of Potentially Dilutive Securities	'
	The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect):
			For the year ended
			December 31,
			2013			2012
	Preferred stock (on an as converted basis)			-			860,017
	Preferred stock warrants			-			20,549
	Outstanding stock options			633,482			590,047
	Unvested restricted stock			-			2,899
	Common stock warrants			53,159			32,610

Subsequent_Events_Tables

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Schedule Of Future Minimum Lease Payments	'
	Future minimum lease payments are as follows:
	2014	$	82,353
	2015		183,137
	2016		188,631
	2017		194,290
	2018		200,119
	Total	$	848,530

Organization_Details

Organization (Details) (USD $)	Jun. 25, 2012	Dec. 31, 2013	Dec. 31, 2012	Apr. 28, 2009	Apr. 30, 2012	Apr. 18, 2012	Apr. 28, 2009	Jun. 30, 2012
		Heat Biologics I, Inc [Member]	Heat Biologics I, Inc [Member]	Heat Biologics I, Inc [Member]	Heat Biologics II, Inc. [Member]	Heat Biologics II, Inc. [Member]	Heat Biologics II, Inc. [Member]	Related Party [Member]
								Heat Biologics II, Inc. [Member]
Noncontrolling Interest [Line Items]	'	'	'	'	'	'	'	'
Ownership interest in subsidiary	'	92.50%	92.50%	92.50%	'	'	92.50%	'
Ownership percentage sold	'	'	'	'	92.50%	'	'	'
Fair value, per share	$0.00	'	'	'	'	$0.00	'	'
Issuance of preferred stock, shares	'	'	'	'	'	'	'	3,700,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended		67 Months Ended				12 Months Ended			12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Apr. 28, 2009	Dec. 31, 2012	Apr. 30, 2012	Apr. 28, 2009	Dec. 31, 2013	Dec. 31, 2013
				Heat Biologics I, Inc [Member]	Heat Biologics I, Inc [Member]	Heat Biologics I, Inc [Member]	Heat Biologics II, Inc. [Member]	Heat Biologics II, Inc. [Member]	Heat Biologics II, Inc. [Member]	Furniture and Fixtures [Member]	Computer Equipment [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Capitalized Costs Property And Equipment	$500	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'	'	'	'	'	'7 years	'3 years
Noncontrolling Interest [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Ownership interest in subsidiary	'	'	'	92.50%	92.50%	92.50%	'	'	92.50%	'	'
Ownership percentage sold	'	'	'	'	'	'	'	92.50%	'	'	'
Sale of subsidiary, date	'	'	'	'	'	'	25-Jun-12	'	'	'	'
Restricted cash	1,252	26,214	1,252	'	'	'	'	'	'	'	'
Minimum cash balance to pay trademark fees	1,000	'	1,000	'	'	'	'	'	'	'	'
Minimum cash balance with lending bank	25,000	'	25,000	'	'	'	'	'	'	'	'
Cash balance insured	250,000	'	250,000	'	'	'	'	'	'	'	'
Cash balance uninsured	4,046,451	'	4,046,451	'	'	'	'	'	'	'	'
Reverse stock split, conversion ratio	0.4348	'	'	'	'	'	'	'	'	'	'
Beneficial conversion charge	2,300,000	'	2,300,000	'	'	'	'	'	'	'	'
Effective conversion price, per share	$6.14	'	$6.14	'	'	'	'	'	'	'	'
Fair value, per share	$8.81	'	$8.81	'	'	'	'	'	'	'	'
Marketing Expense	$135,366	$5,921	$183,274	'	'	'	'	'	'	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Assumptions Used in Valuation of Warrants) (Details) (Stock Warrants Liability [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Exercise price	$4.83	$4.83
Risk-free interest rate	2.75%	1.78%
Expected life (years)	'	'10 years
Expected dividend yield	0.00%	0.00%
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Expected volatility	71.60%	75.60%
Expected life (years)	'7 years 11 months 16 days	'
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Expected volatility	71.90%	76.30%
Expected life (years)	'8 years 7 months 6 days	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Schedule of Change in Fair Value of the Level III Common Stock Warrant Liability ) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Fair value, beginning balance	$92,150
Issuances	'
Change in fair value during the period	30,440
Fair value, ending balance	$122,590

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Schedule of Changes In Fair Value of Level III Stock Warrants Liability) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Stock Warrant Liability	($122,590)	($92,150)
Total Liabilities measured at fair value	-122,590	-92,150
Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Stock Warrant Liability	'	'
Total Liabilities measured at fair value	'	'
Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Stock Warrant Liability	'	'
Total Liabilities measured at fair value	'	'
Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Stock Warrant Liability	-122,590	-92,150
Total Liabilities measured at fair value	($122,590)	($92,150)

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	1 Months Ended						1 Months Ended	12 Months Ended
	Jun. 30, 2012	Oct. 20, 2011	Dec. 31, 2013	Dec. 31, 2012	Apr. 28, 2009	Apr. 28, 2009	Jun. 30, 2012	Dec. 31, 2012	Jun. 25, 2012
			Heat Biologics I, Inc [Member]	Heat Biologics I, Inc [Member]	Heat Biologics I, Inc [Member]	Heat Biologics II, Inc. [Member]	Related Party [Member]	Related Party [Member]	Related Party [Member]
							Heat Biologics II, Inc. [Member]	Heat Biologics II, Inc. [Member]	Heat Biologics II, Inc. [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'	'
Ownership interest in subsidiary	'	'	92.50%	92.50%	92.50%	92.50%	'	'	'
Interest rate	'	12.00%	'	'	'	'	'	'	6.00%
Cash proceeds	$9,250	'	'	'	'	'	$9,250	'	'
Receivable	296,224	'	'	'	'	'	296,244	'	'
Fair value of receivable	'	'	'	'	'	'	'	'	0
Reduction to loss from discontinued operations	'	'	'	'	'	'	'	$9,250	'

Investments_Schedule_of_HeldTo

Investments (Schedule of Held-To-Maturity Investments) (Details) (Certificates of deposit, commercial paper [Member], USD $)	Dec. 31, 2013
Certificates of deposit, commercial paper [Member]	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'
Amortized Cost	$17,297,165
Gross Unrealized Losses	16,493
Estimated Fair Value	17,280,672
Less than 1 year	17,297,165
Total	$17,297,165

Property_and_Equipment_Schedul

Property and Equipment (Schedule of Property and Equipment ) (Details) (USD $)	12 Months Ended		67 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'
Total	$63,312	$13,993	$63,312
Accumulated depreciation	-9,559	-3,211	-9,559
Property and equipment, net	53,753	10,782	53,753
Depreciation	6,348	2,587	9,559
Minimum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful lives	'5 years	'	'
Maximum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful lives	'7 years	'	'
Furniture and fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Total	10,780	10,780	10,780
Estimated useful lives	'7 years	'	'
Computers [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Total	13,175	3,213	13,175
Estimated useful lives	'3 years	'	'
Lab equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Total	$39,357	'	$39,357

Accrued_Expenses_Schedule_of_A

Accrued Expenses (Schedule of Accrued Expenses) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued Expenses [Abstract]	'	'
Compensation and related benefits	$356,588	$105,927
Accrued patent fees	40,000	20,000
Miscellaneous Expenses	106,462	3,281
Total	$503,050	$129,208

Debt_Issuance_Costs_Narrative_

Debt Issuance Costs (Narrative) (Details) (USD $)	12 Months Ended		67 Months Ended	1 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Aug. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
				Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Debt Issuance Cost	'	'	'	$31,680	$55,890	'	'
Debt Instrument, Term	'	'	'	'4 years	'3 years	'	'
Interest Expense, Debt	'	'	'	'	'	'	883
Amortization of debt issuance costs	28,229	58,458	126,742	'	'	'	'
Accumulated amortization	'	3,451	'	'	'	'	'
Amortized and written off debt issuance cost	'	'	'	'	'	$55,007	'

Convertible_Notes_Payable_Narr

Convertible Notes Payable (Narrative) (Details) (USD $)	1 Months Ended
	Oct. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Oct. 20, 2011
Debt Instrument [Line Items]	'	'	'	'
Debt instrument, carrying amount	'	'	'	$950,000
Interest rate	'	'	'	12.00%
Debt conversion description	'The note is convertible into common or Series A preferred stock at the latest valuation. The type of security converted will depend on whether common or Series A preferred stock is issued as part of a successful future equity raise of at least $7.5 million at the qualified offering price.	'	'	'
Maturity date	31-Oct-19	'	'	'
Accrued interest	'	25,364	13,763	'
Convertible notes payable	'	'	$197,099	'

Notes_Payable_Narrative_Detail

Notes Payable (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

Oct. 31, 2011

Dec. 31, 2013

Oct. 20, 2011

Aug. 31, 2012

Dec. 31, 2011

Jul. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 14, 2013

Dec. 14, 2012

Dec. 31, 2011

Dec. 14, 2011

Dec. 14, 2011

Aug. 31, 2012

Dec. 31, 2012

Aug. 07, 2012

Aug. 31, 2013

Aug. 31, 2014

Aug. 07, 2012

Aug. 07, 2012

Jul. 31, 2013

Aug. 31, 2012

Aug. 07, 2012

Jan. 31, 2013

Jan. 10, 2013

Jan. 10, 2013

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

North Carolina Biotechnology Center Loan Agreement [Member]

Loan And Security Agreement Tranche A [Member]

Loan And Security Agreement Tranche A [Member]

Loan And Security Agreement Tranche A [Member]

Loan And Security Agreement Term Loan B [Member]

Loan And Security Agreement Term Loan B [Member]

Loan And Security Agreement Term Loan B [Member]

Loan And Security Agreement Term Loan B [Member]

Loan And Security Agreement [Member]

Loan And Security Agreement [Member]

Loan And Security Agreement [Member]

Loan And Security Agreement Second Amendment [Member]

Loan And Security Agreement Second Amendment [Member]

Loan And Security Agreement Second Amendment [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Maximum [Member]

Maximum [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Maximum [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal loan amount

'

'

$950,000

'

'

'

'

'

'

'

'

'

$250,000

'

'

$1,000,000

'

'

'

$225,000

'

'

'

'

'

$200,000

Annual installments

'

'

'

'

'

'

'

'

5.00%

5.00%

'

'

'

'

'

'

5.00%

5.00%

'

'

'

'

'

'

'

'

Accrues interest, annual

'

'

'

'

'

'

'

'

4.25%

4.25%

'

'

'

'

'

6.00%

'

'

4.25%

'

'

'

'

'

'

'

Accrues interest, monthly

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

200,000

'

Collateral amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

Maturity date

31-Oct-19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9-Jan-14

'

'

Loan amount drew down

'

'

'

'

'

'

225,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock shares purchased by warrant issued

'

'

'

'

'

'

'

'

'

'

'

29,762

'

'

'

'

'

'

'

'

'

'

17,500

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

$4.83

'

'

'

'

'

'

'

'

'

'

$4.83

'

'

'

'

Warrant expiration date

'

'

'

'

'

'

'

'

'

'

13-Dec-21

'

'

'

'

'

'

'

'

'

'

7-Aug-22

'

'

'

'

Term of loan

'

'

'

'4 years

'3 years

'

'

'

'

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

Periodic payments, frequency

'

'

'

'

'

'

'

'

'

'

'

'

'

'Monthly

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of note payable and bank loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$725,000

'

'

'

'

'

'

'

'

'

Reverse stock split, conversion ratio

'

0.4348

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Warrants Post Reverse Stock Split

'

'

'

'

'

12,940

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,609

'

'

'

'

'

License_Agreements_Schedule_of

License Agreements (Schedule of Future Minimum Royalty Payments) (USD $)	Dec. 31, 2013
License Agreements [Abstract]	'
2014	$30,000
2015	30,000
2016	30,000
2017	280,000
2018	30,000
Thereafter	120,000
Total	$520,000

License_Agreements_Narrative_D

License Agreements (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

67 Months Ended

1 Months Ended

1 Months Ended

Jul. 31, 2011

Dec. 31, 2010

Apr. 30, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Mar. 31, 2022

30-May-17

Dec. 31, 2011

Sep. 08, 2010

Jun. 26, 2009

Dec. 31, 2010

Jun. 30, 2009

Apr. 30, 2009

Jul. 31, 2008

Apr. 30, 2011

Apr. 30, 2011

Feb. 28, 2011

Feb. 28, 2011

Feb. 28, 2011

Feb. 28, 2011

Feb. 28, 2011

Dec. 19, 2011

Jun. 30, 2009

Jun. 30, 2009

University [Member]

University [Member]

University [Member]

University [Member]

Not for profit corporation fee one [Member]

Not for profit corporation fee two [Member]

License Agreement ("143") [Member]

License Agreement ("143") [Member]

License Agreement ("J110") [Member]

License Agreement ("J110") [Member]

License agreement ("SS114A") [Member]

Heat Biologics I, Inc [Member]

Heat Biologics I, Inc [Member]

Heat Biologics II, Inc. [Member]

Patent [Member]

Patent [Member]

Not for profit corporation fee two [Member]

Not for profit corporation fee two [Member]

Additional consideration

'

'

$12,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum royalty payment for first three years, per year

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum royalty payment for remainer life of agreement, per year

'

'

'

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payment

'

'

'

'

'

'

400,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License Costs

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

5,000

50,000

'

14,158

'

1,055

'

'

'

'

Option fees

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement of for past patent fees

'

15,797

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

10,000

'

37,381

'

'

'

Exercise of stock options

10,000

'

'

54,042

'

54,042

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unpaid License Fees

'

'

'

'

'

'

'

'

$160,000

'

'

'

'

'

'

'

'

'

'

'

'

'

$102,784

'

'

Annual interest on outstanding balance

'

'

'

18.00%

'

18.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of all issued and outstanding stock to be issued with license agreement

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

2.50%

10.00%

'

'

'

'

'

'

'

'

'

'

Percentage of issued and outstanding stock owned

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.50%

7.50%

Stock_Warrants_Liability_Detai

Stock Warrants Liability (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrant [Member]	'	'	'
Common Stock Warrants	'	'	'
Outstanding, beginning balance	20,549	12,940	'
Granted	'	7,609	'
Exercised	'	'	'
Expired/cancelled	'	'	'
Outstanding, ending balance	20,549	20,549	12,940
Weighted Average Exercise Price	'	'	'
Outstanding, at the beginning of year	$4.83	$4.83	'
Granted	'	$4.83	'
Exercised	'	'	'
Expired/cancelled	'	'	'
Outstanding, at the end of year	$4.83	$4.83	$4.83
Weighted Average Remaining Contractual Life (in years)	'	'	'
Outstanding	'8 years 2 months 12 days	'8 years 10 months 24 days	'9 years 10 months 24 days
Granted	'	'9 years 10 months 24 days	'
Weighted Average Grant Date Fair Value	'	'	'
Outstanding, at the beginning of year	$1.64	$1.91	'
Granted	'	$1.81	'
Exercised	'	'	'
Expired/cancelled	'	'	'
Outstanding, at the end of year	$5.95	$1.64	$1.91
Aggregate Intrinsic Value	'	'	'
Aggregate intrinsic value of preferred stock warrants	$46,646	'	'

Stockholders_Equity_Deficit_Na

Stockholders' Equity (Deficit) (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

67 Months Ended

1 Months Ended

12 Months Ended

Sep. 30, 2013

Aug. 31, 2013

Jul. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Series 1 Preferred Stock [Member]

Series 1 Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B-1 Preferred Stock [Member]

Series B-1 Preferred Stock [Member]

Series B-2 Preferred Stock [Member]

Stockholders' Equity (Deficit) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value per share

'

'

'

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

50,000,000

50,000,000

50,000,000

'

'

'

'

'

'

'

'

Common stock, shares issued

'

'

'

6,375,426

2,144,542

6,375,426

'

'

'

'

'

'

'

'

Common stock, shares outstanding

'

'

'

6,375,426

1,858,971

6,375,426

'

'

'

'

'

'

'

'

Shares issued for initial public offering

100,000

100,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

Price per share

$10

$10

$10

'

'

'

'

'

'

'

'

'

'

'

Proceeds from initial public offering

$1,000,000

$1,000,000

$25,000,000

$27,000,000

'

'

'

'

'

'

'

'

'

'

Proceeds from initial public offering, net

930,000

930,000

22,400,000

24,300,000

'

'

'

'

'

'

'

'

'

'

Common stock issued for conversion of preferred stock

'

'

'

1,696,683

'

'

'

'

'

'

'

'

'

'

Shares issued as stock dividend

'

'

'

36,167

'

'

'

'

'

'

'

'

'

'

Preferred stock dividend

'

'

'

361,668

'

361,668

'

'

'

'

'

'

'

'

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, par value per share

'

'

'

'

'

'

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

Preferred stock, shares authorized

'

'

'

'

'

'

112,500

112,500

2,000,000

2,000,000

4,100,000

'

'

'

Preferred stock, shares issued

'

'

'

'

'

'

0

112,500

0

1,863,128

'

'

'

'

Preferred stock, shares outstanding

'

'

'

'

'

'

0

112,500

0

1,863,128

'

'

'

'

Price per share

'

'

'

'

'

'

$2.35

'

$2.10

'

'

'

$2.67

$5

Minimum net proceeds from public offering for automatic conversion

'

'

'

15,000,000

'

15,000,000

'

'

'

'

'

'

'

'

Reverse stock split, conversion ratio

'

'

'

0.4348

'

'

'

'

'

'

'

'

'

'

Shares issuable upon conversion of preferred stock

'

'

'

0.4348

'

0.4348

'

'

'

'

'

'

'

'

Preferred stock, dividend rate

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

5.00%

Preferred stock, dividend amount per share

'

'

'

'

'

'

'

'

'

'

'

'

$6.14

$11.50

Preferred stock, liquidation preference

'

'

'

'

'

'

$4.83

'

$5.41

'

'

'

$6.14

$11.50

Proceeds from issuance of private placement

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

'

Issuance of preferred stock, shares

'

'

'

'

'

'

'

'

'

'

'

1,891,419

'

'

Stockholders_Equity_Deficit_Sc

Stockholders' Equity (Deficit) (Schedule of Restricted Stock Activity) (Details) (Restricted Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Restricted Stock [Member]	'
Shares	'
Unvested, beginning balance	2,899
Vested	-2,899
Unvested, ending balance	'
Weighted-average grant date fair value	'
Unvested, beginning balance	$2.23
Vested	$8.81
Unvested, ending balance	'

Stockholders_Equity_Deficit_Co

Stockholders' Equity (Deficit) (Common Stock Warrants) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expiration term	'10 years	'	'
Common Stock Warrants [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Warrant liabilities outstanding	20,549	'	'
Exercise price of warrant liabilities	4.83	'	'
Expiration term	'10 years	'10 years	'10 years
Exercise price	'	'	$0.48
Price per share	$12.50	'	'
Common Stock Warrants	'	'	'
Outstanding, beginning balance	53,159	45,550	'
Granted	125,000	7,609	32,610
Exercised	'	'	'
Expired	'	'	'
Outstanding, ending balance	178,159	53,159	45,550

Stockholders_Equity_Deficit_Eq

Stockholders' Equity (Deficit) (Equity Compensation Plan) (Narrative) (Details) (USD $)	12 Months Ended		67 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2009
Stockholders' Equity (Deficit) [Abstract]	'	'	'	'	'
Stock Incentive Plan, shares authorized	1,500,000	'	1,500,000	'	500,000
Expiration term	'10 years	'	'	'	'
Outstanding stock options	633,482	590,047	633,482	471,905	'
Stock-based compensation expense	$571,924	$217,896	$925,959	'	'
Weighted average grant-date fair value	$8.51	$1.31	'	'	'
Fair value of stock options vested	440,820	'	'	'	'
Unrecognized stock-based compensation expense	$1,604,200	'	$1,604,200	'	'
unrecognized stock-based compensation expense, recognition period	'14 months	'	'	'	'

Stockholders_Equity_Deficit_Sc1

Stockholders' Equity (Deficit) (Schedule of Stock-based Compensation) (Details) (USD $)	12 Months Ended		67 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock based compensation	$571,924	$217,896	$925,959
Outstanding stock options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock based compensation	131,178	60,956	'
Non-employee stock options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock based compensation	415,212	128,157	'
Restricted stock awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock based compensation	$25,534	$28,783	'

Stockholders_Equity_Deficit_Sc2

Stockholders' Equity (Deficit) (Schedule of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Shares	'	'
Outstanding, beginning balance	590,047	471,905
Granted	186,736	178,742
Exercised	-80,706	-22,827
Expired/Cancelled	-62,595	-37,773
Outstanding, ending balance	633,482	590,047
Weighted Average Exercise Price	'	'
Outstanding, beginning balance	$0.71	$0.64
Granted	$10.07	$0.76
Exercised	$0.67	$0.51
Expired/Cancelled	$1.96	$0.02
Outstanding, ending balance	$3.36	$0.71

Stockholders_Equity_Deficit_Sc3

Stockholders' Equity (Deficit) (Schedule of Stock Option Valuation Assumptions) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Dividend yield	0.00%	0.00%
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected volatility	90.00%	80.00%
Risk-free interest rate	1.39%	0.07%
Expected lives (years)	'5 years 9 months	'5 years
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected volatility	112.00%	90.00%
Risk-free interest rate	2.26%	0.97%
Expected lives (years)	'6 years 6 months	'6 years 3 months

Stockholders_Equity_Deficit_Su

Stockholders' Equity (Deficit) (Summary of Outstandng Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Options Outstanding	'
Balance	633,482
Weighted average remaining contractual life	'7 years 3 months 7 days
Weighted Average Exercise Price	$3.36
Options Exercisable	'
Balance	426,423
Weighted average remaining contractual life	'6 years 3 months 22 days
Weighted average exercise price	$1.23
Options Vested or Expected to Vest	'
Balance	426,423
Weighted average remaining contractual life	'6 years 3 months 22 days
Weighted average exercise price	$1.23

Stockholders_Equity_Deficit_Sc4

Stockholders' Equity (Deficit) (Schedule of Nonvested Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Shares	'	'
Outstanding, beginning balance	158,077	248,439
Granted	186,736	178,742
Vested	-91,020	-257,510
Forfeited	-46,734	-11,594
Outstanding, ending balance	207,059	158,077
Weighted Average Exercise Price	'	'
Outstanding, beginning balance	$0.71	$0.64
Granted	$10.07	$0.76
Vested	$0.67	$0.51
Forfeited	$1.96	$0.02
Outstanding, ending balance	$3.36	$0.71

Income_Tax_Schedule_of_Income_

Income Tax (Schedule of Income Tax Expense (Benefit)) (Details) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Current expense:	'	'	'
Federal	'	'	'
State	'	'	'
Current expense	'	'	'
Deferred expense (benefit):	'	'	'
Federal	'	'	'
State	'	'	'
Deferred expense (benefit)	'	'	'
Total	'	'	'

Income_Tax_Schedule_of_Income_1

Income Tax (Schedule of Income Tax Rate Differences) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Abstract]	'	'
Federal income tax expense at statutory rate	($2,247,353)	($840,190)
State and local income taxes, net of federal benefit	-186,475	-105,170
Non-deductible expenses	4,985	54,991
Prior-period true-up	162,061	-152,306
Research & development credit	-180,687	-57,293
Change in tax rate	32,774	'
Increase in valuation allowance	2,414,695	1,099,968
Total	'	'

Income_Tax_Schedule_of_Deferre

Income Tax (Schedule of Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforward	$4,167,785	$2,186,432
Research & development credit	424,739	189,350
Other	247,966	50,013
Valuation allowance	-4,840,490	-2,425,795
Deferred income taxes	'	'

Income_Tax_Narrative_Details

Income Tax (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Tax [Abstract]	'
Statutory federal tax rate	34.00%
Change in valuation allowance	$2,414,695
Operating Loss Carryforwards [Line Items]	'
U.S. net operating loss carryforwards	$20,999,761
Minimum [Member]	'
Operating Loss Carryforwards [Line Items]	'
U.S. net operating loss carryforwards expiration dates	31-Dec-23

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	1 Months Ended		12 Months Ended
	Dec. 31, 2012	Nov. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	Oct. 20, 2011
Commitments and Contingencies [Abstract]	'	'	'	'	'
Lease Agreement Term	'	'13 months	'	'	'
Operating Leases, Rent Expense	$4,046	$3,870	$48,377	$43,341	'
Convertible Notes Payable	'	'	'	'	$950,000

Related_Party_Narrative_Detail

Related Party (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

67 Months Ended

12 Months Ended

67 Months Ended

12 Months Ended

67 Months Ended

12 Months Ended

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Chairman [Member]

Chairman [Member]

Chairman [Member]

Scientific advisory board [Member]

Scientific advisory board [Member]

Scientific advisory board [Member]

Management [Member]

Management [Member]

Management [Member]

Clinical advisory board one [Member]

Clinical advisory board two [Member]

Clinical advisory board three [Member]

Board [Member]

Board [Member]

Minimum [Member]

Maximum [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting fees

'

'

'

'

$18,750

$140,625

'

'

$50,000

$34,480

$30,910

$70,910

$45,000

$16,590

$14,700

'

'

Officers' Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

10,870

Related party payable balance

'

13,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of ownership interest

92.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on receivables

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash

9,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Receivable

296,224

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related party receivable

'

$24,946

$9,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net_Loss_Per_Share_Reverse_Sto

Net Loss Per Share (Reverse Stock Split) (Details)	1 Months Ended	12 Months Ended
	31-May-13	Dec. 31, 2013
Net Loss Per Share [Abstract]	'	'
Reverse stock split, conversion ratio	'	0.4348
Reverse stock split	'.4348	'

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share (Schedule of Antidilutive Securities) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Preferred stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities	'	860,017
Preferred stock warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities	'	20,549
Outstanding stock options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities	633,482	590,047
Unvested restricted stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities	'	2,899
Common Stock Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities	53,159	32,610

Net_Loss_Per_Share_Schedule_of1

Net Loss Per Share (Schedule of Reconciliation of Net Loss Applicable to Common Shareholders) (Details) (USD $)	7 Months Ended	12 Months Ended				67 Months Ended
	Dec. 31, 2008	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2009	Dec. 31, 2013
Net Loss Per Share [Abstract]	'	'	'	'	'	'
Net Loss	($281,971)	($6,609,864)	($2,471,147)	($2,113,142)	($423,439)	($12,621,407)
Net loss - non-controlling interest	'	-198,516	-50,947	'	'	-274,777
Beneficial conversion charge	'	-2,300,000	'	'	'	-2,300,000
Preferred stock dividend	'	-361,668	'	'	'	-361,668
Net loss attributable to common stockholders	'	($9,073,016)	($2,420,200)	'	'	($15,008,298)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted	'	3,747,357	1,831,769	'	'	'
Net loss per share attributable to common stockholders-basic and diluted	'	($2.42)	($1.32)	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended		12 Months Ended
	Dec. 31, 2012	Nov. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	1-May-14	Mar. 31, 2014
					Subsequent Event [Member]	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'
2014	'	'	'	'	$82,353	'
2015	'	'	'	'	183,137	'
2016	'	'	'	'	188,631	'
2017	'	'	'	'	194,290	'
2018	'	'	'	'	200,119	'
Total	10,000	'	'	10,000	848,530	'
Total rent expense	4,046	3,870	48,377	43,341	'	'
Obligation upon completion of phase I clinical trial	'	'	'	'	'	50,000
Obligation upon completion of phase II clinical trial	'	'	'	'	'	100,000
Obligation upon completion of phase III clinical trial	'	'	'	'	'	100,000
Obligation upon acceptance of BLA by FDA or foreign equivalent	'	'	'	'	'	$100,000